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Current models hold that organ dysfunction in acute pancreatitis is mediated through
a systemic inflammatory response characterised by the secretion of pro-inflammatory
mediators and the activation of leukocytes and their subsequent interaction with
activated endothelial cells. Although pancreatic inflammation is the initial trigger for
the systemic inflammatory response, recent evidence suggests that it is maintained in
part by intestinal tract dysfunction, which in turn is partly mediated by the loss of
enteral nutrition. The aim of this thesis is to investigate the basis for disease severity
in acute pancreatitis, and to assess a novel therapeutic intervention in patients with
severe acute pancreatitis.
1) To provide evidence for the presence of endothelial cell activation the kinetics of
serum soluble E-selectin and P-selectin in 18 patients with acute pancreatitis
were determined. In all patients soluble P-selectin concentrations decreased
significantly over the study period. Non-survivors had significantly higher levels
of soluble P-selectin than survivors. In contrast, soluble E-selectin increased
significantly over the study period in patients with organ dysfunction, whilst
remaining constant in patients without evidence of organ dysfunction.
2) Cytokines such as TNFa and IL1P and their endogenous antagonists such as
IL1RA are important mediators of disease severity in acute pancreatitis. Because
secretion of these cytokines is partly determined by genetic factors the
distribution of TNF-308, TNFB, IL1 (3 Taql and IL1RN gene polymorphisms
were determined for 190 individuals with acute pancreatitis. The frequency of
the polymorphisms studied were similar in patients with mild or severe acute
pancreatitis. Moreover there was no significant difference in genotype frequency
in patients with acute pancreatitis when compared to 102 healthy controls.
3) To further assess the influence of genetic factors, cytokine phenotype for TNFa,
IL1(3 and IL1RA was determined in 51 individuals following recovery. With
respect to phenotype, secretion ofTNFa was similar in patients with previous
mild or severe acute pancreatitis, however the ILipdLIRA ratio was
significantly lower in patients with previous severe acute pancreatitis than those
with mild disease.
4) To assess the potential benefits from the introduction of enteral nutrition in
patients with severe acute pancreatitis a randomised clinical trial was undertaken.
Patients were randomised to receive either enteral nutrition or conventional
therapy consisting of a nil-by-mouth regime. Of 27 patients, 13 patients received
enteral nutrition. A median of 21 % of calorific requirements were delivered over
the first 4 days by enteral nutrition. There were no significant complications of
enteral nutrition. The introduction of enteral nutrition did not significantly affect
the concentrations of serum IL6, serum sTNFR-I or serum CRP over the first 4
days of the study period. Although there was no significant differences in
intestinal permeability between the two patient groups at admission, by day 4
abnormal intestinal permeability occurred more frequently in patients receiving
enteral nutrition.
The present studies therefore suggest:
1) A role for endothelial-derived selectins in the development of organ dysfunction
in patients with acute pancreatitis. Further, the observed temporal differences in
serum selectin concentrations is in keeping with in-vitro observations of
endothelial selectin expression.
2) That genetic factors may not be important in determining TNFa secretion in
patients with acute pancreatitis. However, a pre-determined imbalance between
ILip and its antagonist IL1RA would appear to exist in patients with severe acute
pancreatitis, although the genetic basis for this altered relationship could not be
determined.
3) That early enteral nutrition does not ameliorate the inflammatory response in
patients with prognostically severe acute pancreatitis. Furthermore early enteral
nutrition did not have a beneficial effect on intestinal permeability.
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Introduction
Acute pancreatitis is an acute inflammatory process of the pancreas, with variable
involvement of other regional or remote organ systems 1. It is a common condition
whose incidence appears to be increasing 2. Although the majority of patients with
acute pancreatitis have a mild illness with complete recovery, a substantial
proportion of patients develop severe acute pancreatitis. Those patients with severe
disease have high morbidity and mortality rates , with prolonged in-hospital stays
and as a consequence have significant healthcare economic implications 4.
Despite extensive research into the pathogenic mechanisms of acute pancreatitis it is
still not clear why a group of patients develop severe disease. Moreover, there are
few specific therapeutic interventions for the treatment of acute pancreatitis, and the
small improvement in outcome observed over the last couple of decades for patients
with severe acute pancreatitis is probably mainly due to improvements in critical care
medicine.
With this background in mind the aim of this thesis is to investigate the basis for
disease severity in acute pancreatitis, and to assess a novel therapeutic intervention in
patients with severe acute pancreatitis.
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Demographics OfAcute Pancreatitis
The most recent analysis of Scottish Morbidity Record (SMR) data collected by the
Information and Statistics Division (ISD) demonstrated that the incidence of acute
pancreatitis in Scotland in 1995 was 41.9 cases per 100,000 population per year .
This rate is similar to the incidence of acute pancreatitis in Sweden (38.2 per
100,000/year)5 and in Norway (41.5 per 100,000/year)6, but is considerably less
than in Finland (73.4 per 100,000/year)1. The reason for the difference in the
incidence of acute pancreatitis between Scotland and Finland is not clear, but may be
due to variation in the prevalence of aetiological agents within each population; the
high rate of acute pancreatitis in Finland is associated with a high rate of alcohol
consumption within the male population 1.
However, of greater public health concern is the observation that the incidence of
acute pancreatitis appears to be increasing. In Scotland during the period 1961 to
1985, a rise from 13.0 to 22.5 cases per 100,000/year occurred , although during this
period the Phadebas test for the measurement of serum amylase was introduced
making the diagnosis of acute pancreatitis easier. However, a further increase to
41.9 per 100,000/year in 1995 has subsequently been observed . Significantly,
similar studies from Bristol 9'10, Nottingham ", Birmingham 12, Gottingen
IT 7
Germany and Finland have also demonstrated an increase in the incidence of
acute pancreatitis. The reason for the observed increase in incidence within each
populations is not clear, although in Finland the increase in the incidence of acute
pancreatitis is strongly correlated with an increase in alcohol consumption 1.
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Aetiology OfAcute Pancreatitis
A number of agents can cause acute pancreatitis (Table 1), although the two most
common causes are gallstones and excessive alcohol ingestion; in the United
Kingdom gallstones are the most common agent inducing acute pancreatitis. The
remaining aetiological agents account for relatively few cases of acute pancreatitis.
Further, in spite of extensive investigation the causative agent is frequently not
identified. These cases are therefore termed idiopathic acute pancreatitis. It is
probable that the number of cases labelled as idiopathic is inversely related to the
degree of investigation. Recent United Kingdom guidelines state that the diagnosis
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Table 1: Aetiological agents in acute pancreatitis.
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Pathogenesis OfAcute Pancreatitis
Despite extensive research the pathogenic mechanisms in acute pancreatitis have not
yet been fully elucidated. Although a number of disparate agents may induce acute
pancreatitis, it is believed that following the initial pancreatic acinar cell injury the
pathogenic mechanisms in acute pancreatitis are the same regardless of aetiology.
That is, the pathogenic mechanisms giving rise to organ dysfunction in patients with
gallstone-induced severe acute pancreatitis are the same mechanisms giving rise to
organ dysfunction in alcohol-induced severe acute pancreatitis. Likewise, it is
thought that the same basic pathogenic mechanisms underpin both mild and severe
acute pancreatitis and that the difference in the clinical picture and outcome is the
result of quantitative differences within the pathogenic mechanisms. The reasons for
the quantitative differences in the pathogenic mechanisms are not known.
Early Acute Pancreatitis - The Initial Pancreatic Acinar Cell Injury
Various hypotheses have been proposed by which each aetiological agent causes the
initial pancreatic acinar cell injury.
Opie initially proposed that gallstones triggered acute pancreatitis in patients in
whom the common bile duct formed a common channel with the main pancreatic
duct allowing bile to reflux into the pancreatic duct following impaction of a
gallstone at the ampulla ofVater. This has become known as the "common channel"
theory, and despite a large volume of evidence against it 15 the theory remains
popular. Against the theory is the anatomical observation that any "common
channel" would be too short to allow reflux of bile into the pancreatic duct during
stone impaction 16. Further, during the initial stages pancreatic duct pressure would
be higher than bile duct pressure promoting instead pancreatico-biliary reflux 17'18.
Similarly, although perfusion of the pancreatic duct with various solutions, including
enterokinase-activated pancreatic juice and taurocholate, induces acute pancreatitis in
the experimental situation 19'20, other studies have suggested that the perfusion of
9
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sterile bile at physiological pressures may not induce acute pancreatitis ' . It is
however probable that increased pancreatic duct pressure is the key factor which
results in pancreatic acinar cell injury in gallstone-induced disease, although the
mechanism through which it mediates acinar cell injury is not known.
Similarly, the mechanisms through which ethanol induces acute pancreatitis have not
been elucidated. The postulated initial pathogenic mechanisms of alcohol-induced
99
pancreatitis can be broken down into three broad areas " (Table 2); "big duct"
hypothesis, "small duct" hypothesis and acinar cell injury. The original "big duct"
hypothesis was based on Opie's hypothesis regarding the pathogenesis of
gallstone-induced disease, and held that acute pancreatitis was a consequence of
biliary obstruction due to alcohol-induced sphincter of Oddi spasm or duodenitis in
individuals with a common channel allowing bilio-pancreatic reflux. However,
subsequent studies have provided cogent evidence against the original and
subsequent variants of the big duct theory24. More probable explanations may be
provided by the "small duct" and acinar cell injury theories, although it should be
9 S
noted that neither of these theories is mutually exclusive. Sarles and Sahel
postulated that precipitation of protein plugs within pancreatic ductules is an
important early event resulting in obstruction. Although precipitation of protein is
due in part to increased protein concentration 26, increased pancreatic acinar cell
secretion of lactoferrin, an iron containing protein which has the ability to stimulate
• • • 97
acidophilic protein aggregation, also occurs . The cause of the abnormal protein
secretion is not known.
Other potential mechanisms of alcohol-induced acinar cell injury exist. As in
alcoholic liver disease a toxic ethanol metabolite, such as acetaldehyde, may be the
cause of the pancreatic acinar cell injury 23. Although acetaldehyde may be directly
toxic to the pancreatic acinar cell, metabolisation of acetaldehyde by xanthine




Finally, alcohol-induced acute pancreatitis may be the consequence of abnormal
trafficking of proteins within the pancreatic acinar cell, whereby co-localisation of
digestive pro-enzymes and lysosomal enzymes occurs with subsequent secretion of
activated pancreatic enzymes into the pancreatic parenchyma leading to the induction
of acute pancreatitis 24.
Big duct hypotheses
Biliary-pancreatic reflux















Table 2: Potential mechanisms through which alcohol induces acute
pancreatitis.
Early Acute Pancreatitis - Abnormal Intracellular Physiology
Although the pathogenic mechanisms through which an initiating stimulus causes
pancreatic acinar cell injury may differ, it is believed that a common pathway exists
through which abnormal intracellular metabolism leads to the premature activation of
pancreatic exocrine pro-enzymes in an inappropriate location.
Experimental studies have suggested that the pro-enzyme trypsinogen is important.
Under normal physiological conditions, following secretion of trypsinogen into the
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lumen of the small intestine, trypsinogen is cleaved through the action of
enterokinase to the active enzyme trypsin. However, within cell culture, intracellular
activation of trypsinogen can be provoked in isolated pancreatic acinar cells using
stimuli which in animal models may induce acute pancreatitis. Similarly in
experimental animal models of acute pancreatitis intracellular activation of
trypsinogen can be observed alongside aberrant trypsinogen activation within the
pancreatic parenchyma 2 '30. The cause of the aberrant activation and secretion of
trypsinogen is not clear, although a disturbance in normal calcium metabolism has
been implicated 31'32.
Further evidence supporting the role of intracellular activation of trypsinogen in the
pathogenesis of acute pancreatitis comes from the identification of mutations
predisposing to hereditary acute pancreatitis within the cationic trypsinogen gene.
Under normal conditions auto-activation of cationic trypsinogen occurs at low levels,
however a number of protective mechanisms exist to prevent cellular damage. In the
first instance, an intracellular peptide termed pancreatic secretory trypsin inhibitor
•••• 33
(PSTI) exists which irreversibly binds to trypsin thereby inactivating it . However,
if levels of intracellular trypsin exceed the capacity of pancreatic secretory trypsin
inhibitor, trypsin itself activates intracellular proteases which in turn cleave the
activated trypsin thereby neutralising it. In hereditary pancreatitis a mutation occurs
within the cationic trypsinogen gene rendering cationic trypsin resistant to the action
of intracellular proteases 34, negating the effect of the negative feedback mechanism.
Acute Pancreatitis - Local Pancreatic Inflammation
The effect of premature activation of intracellular and intra-parenchymal trypsinogen
is the induction of local pancreatic inflammation.
In the early stages of acute pancreatitis leukocytes accumulate within the pancreas,
their numbers correlating with the severity of the acute pancreatitis 35>365 and
T7
pancreatic capillaries demonstrate increased permeability ' . The pathogenesis of
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the local acute inflammatory response appears similar to that at any other site. A
large number of interacting mechanisms and mediators have been implicated in local
pancreatic inflammation (Table 3). Moreover, experimental studies in animal
models have demonstrated reduced pancreatic inflammation following interventions
aimed at perturbing these mechanisms. Although the inflammatory response is likely
to be triggered by the aberrant secretion of pancreatic enzymes into the pancreatic
parenchyma other mechanisms may also play a role. Pancreatic acinar cells have the
ability to express pro-inflammatory cytokines and chemokines following an
insult 39'40. Further, once initiated, the inflammatory process may become
• • • Tf\ •
independent of further protease activation , that is the local inflammatory response
may become self sustaining.
Proteases (e.g. trypsin)









Table 3: Mediators and mechanisms of local pancreatic inflammation.
Acute Pancreatitis - Systemic Inflammatory Response
Acute pancreatitis has long been recognised as having effects distant from the
pancreas gland. It is these remote effects which, in part, distinguish those patients
with severe acute pancreatitis from those with mild disease '. Original hypotheses
held that multiple organ dysfunction in acute pancreatitis arose as a consequence of
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circulating activated digestive enzymes causing systemic "autodigestion". However,
following the failure of protease inhibitors to ameliorate the disease process 41 and
more recent evidence derived from both human and experimental animal models
newer models have been proposed. Rinderknecht42 hypothesised that an excessive
systemic inflammatory response is responsible for the development ofmultiple organ
dysfunction, and that the mechanisms responsible for the development ofmultiple
organ dysfunction in acute pancreatitis are fundamentally the same as those found in
other critical illness states. Current models therefore hold that organ dysfunction in
acute pancreatitis is the consequence of a systemic inflammatory response which is
characterised by the secretion of inflammatory mediators, the activation of
leukocytes and their interaction with endothelial cells 43.
Inflammatory mediators
Tumour necrosis factor
Tumour necrosis factor a (TNFa) and tumour necrosis factor p (TNFP) are members
of the tumour necrosis factor ligand and receptor family. This group of biologically
active molecules consists of 10 known ligands with similar biological properties. In
general, members of the tumour necrosis factor superfamily play major roles in the
pathogenesis of inflammation-mediated diseases.
TNFa was the first described member of the tumour necrosis factor ligand family
and was so named because of its ability to cause necrosis within transplantable
tumours 44. However, despite initial expectations that TNFa could be used as a
novel anti-cancer agent, subsequent studies in both animals and humans
demonstrated highly toxic effects, with TNFa effecting a state akin to septic shock.
Indeed, TNFa has subsequently been demonstrated to be a potent pro-inflammatory
mediator with a key role in the development of the systemic inflammatory response
syndrome and multiple organ failure.
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TNFa is a 233 amino acid, non glycosylated polypeptide which exists in both a
26kDa membrane associated form and a 17kDa soluble form 45~47. The 17kDa
soluble form arises from proteolytic cleavage ofmembrane-associated TNFa
through the action of TNFa converting enzyme 48'49. Soluble 17kDa TNFa
combines non-covalently to form a homotrimeric complex, which spontaneously
decays with a half life of 5-10 minutes 50'51. Although both the
membrane-associated and the soluble homotrimer are biologically active, soluble
• S9 ST
homotrimeric TNFa is the more potent ' .
Tumour necrosis factor P (TNFP) or lymphotoxin is a 171 amino acid residue,
25kDa glycosylated polypeptide 54 which has 28% homology with TNFa 45'55. In
contrast to TNFa, TNFp does not have a transmembrane form, existing solely as a
biologically active soluble homotrimeric form. TNFp may however be membrane
56 57associated through its interaction with membrane associate lymphotoxin p " ' .
Although the biological effects of TNFp are similar to those of TNFa, little is known
about its role in human critical illness states because the emphasis of research has
been focussed on TNFa.
TNFa is secreted by many different cells, although the principal cellular sources are
derived from the monocyte/macrophage cell line. TNFa secretion is stimulated by a
number of bacterial, viral, parasitic and tumour related products, as well as other
pro-inflammatory mediators including TNFa itself58. One of the most potent
stimuli is endotoxin, a lipopolysaccharide derived from the outer membrane of gram

















Mediation of hepatic acute phase protein synthesis
Decreased synthesis -Albumin
Table 4: The effects of TNFa 59.
Evidence derived from both experimental models and clinical studies has
demonstrated that TNFa is an important early mediator in the development of the
systemic inflammatory response syndrome and multiple organ dysfunction 59. In
experimental animal models the administration of gram-negative bacteria increases
the level of circulating serum TNFa, provoking a state similar to septic shock 60.
Moreover the infusion of TNFa alone is sufficient to provoke the septic state 61,
whilst antagonism of TNFa through the administration of either anti-TNFa
f\9 • •
antibodies or recombinant soluble tumour necrosis factor receptors in animal
models of sepsis is associated with an improved outcome.
However, although there is compelling evidence derived from animal experimental
studies for a major role for TNFa in the development of the systemic inflammatory
response and multiple organ dysfunction, data relating to human critical illness states
are less strong. Certainly intravenous infusion of endotoxin provokes signs of a
systemic inflammatory response and is associated with increased levels of
16
TNFa 60'64' 655 whilst the infusion ofTNFa alone induces signs of a systemic
inflammatory response 66~68. However, TNFa is infrequently detected in the serum
of patients with the systemic inflammatory response syndrome or multiple organ
dysfunction 69. Although the failure to detect TNFa in all patients may suggest that
TNFa does not play a role in the pathogenic process, it may also be a manifestation
of sampling error brought on by the very early role ofTNFa in the development of
the inflammatory state coupled with the short half-life of circulating TNFa.
Similarly, although several large clinical trials have demonstrated that blockade of
TNFa activity does not improve outcome in patients with the systemic inflammatory
response syndrome 70"75, there are several potential explanations which may explain
these results including the very proximate role of TNFa in the pathogenic process
76
and the overall complexity of the systemic inflammatory response .
As may be predicted, the role of TNFa in the pathogenesis of acute pancreatitis
would appear to be similar to its role in the mediation of the systemic inflammatory
response and multiple organ dysfunction in other critical illness states.
In experimental models of acute pancreatitis, TNFa production occurs initially
• • • 39 77 80within the pancreas and then subsequently within other remote organs ' " ,
although there does appear to be differential organ synthesis ofTNFa with marked
expression in lung, liver and spleen but not in kidney, cardiac muscle or skeletal
muscle 11.
Further, perturbation of the mechanisms leading to TNFa secretion results in
improved outcome in animal models of acute pancreatitis. Inhibition of the p38
MAP kinase intracellular signalling pathway, which is involved in TNFa
• • 81
transcription, ameliorates the acute lung injury in acute pancreatitis . Similarly
prevention ofNFkB mediated tumour necrosis factor gene transcription reduces the
severity of experimental acute pancreatitis 82, whilst inhibition ofTNFa mRNA
translation reduces the severity of the pancreatic and lung injury 83.
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Similarly, evidence demonstrating the importance ofTNFa in the pathogenesis of
acute pancreatitis has been derived from experimental studies which aim to block the
effects of TNFa. Although an initial study which examined the effects of the
administration of a polyclonal anti-TNFa antibody in an animal model of acute
84 • •
pancreatitis suggested a worsening of disease severity , two further studies using
different polyclonal anti-TNFa antibodies have demonstrated improved
outcome 85'86. Moreover, infusion of recombinant soluble TNF receptor I improves
87 • • , 11 • i ...i
outcome . Finally the severity of experimentally induced acute pancreatitis is less
88
in TNF receptor I gene knockout mice when compared to normal wild mice .
Again however, the evidence relating to TNFa in human acute pancreatitis is less
strong when compared to that derived from animal studies. Even in severe acute
pancreatitis, TNFa can only be detected in the serum of a minority of cases 89-93.
The reason for the failure to observe serum TNFa is not clear but again it may be a
consequence of the short half life of TNFa coupled with infrequent blood sampling.
Other explanations may exist. In an animal model of acute pancreatitis, levels of
serum TNFa were significantly higher in portal venous blood compared with
systemic venous blood; the lower systemic levels attributable to hepatic
metabolism 94. Therefore undetectable serum levels may not be indicative of a lack
of TNFa production but may be the result of the compartmentalisation of cytokine
production with the measurement being taken from the "wrong" compartment.
However, in contrast to the infrequent detection of TNFa in the serum of patients
with acute pancreatitis, serum soluble TNF receptors can be detected in all cases with
levels of serum soluble TNF receptor type I 91-95>96 and serum soluble TNF receptor
type II 91 correlating with disease severity. Significantly because levels of serum
soluble TNF receptors correlate with levels of serum TNFa in a human model of
endotoxaemia 97, and infusion of recombinant TNFa provokes a rise in serum
Q8
soluble TNF receptors , serum soluble TNF receptors may be considered as an
indirect measure of previous TNFa exposure. The observations of de Beaux 91,
18
Kaufmann 95 and Soong 96 therefore suggest that there is significant production of
TNFa in patients with severe acute pancreatitis.
The cellular origin of increased systemic TNFa production in acute pancreatitis is
TQ
not clear. Although pancreatic acinar cells can synthesise TNFa , significant first
pass hepatic metabolism of TNFa occurs 94 and therefore other cellular sources of
TNFa are more likely to be involved in the pathogenesis of the systemic
inflammatory response. The most probable source is cells derived from the
monocyte/macrophage line. McKay and colleagues 99 observed that monocytes
isolated from patients with severe acute pancreatitis secrete greater amounts of
TNFa than those from patients with mild disease. However, similar differential
secretion has not been observed with isolated peripheral blood mononuclear cells,
which consists ofmixed monocytes and lymphocytes 10°.
Two types of tumour necrosis factor receptor have been identified. TNF receptor
type I (TNFR-I) is a 55kDa transmembrane protein and is expressed by many cell
types including monocytes and neutrophils 101, endothelial cells 102 and
hepatocytes l03. TNF receptor type II (TNFR-II) is a 75kDa transmembrane receptor
which is expressed on a variety of cell types including monocytes 1 4,
macrophages 105 and endothelial cells 106. The relative importance of each type of
receptor in mediating intracellular events is not clear. Initial studies suggested that
the majority ofTNFa effects were mediated through TNFR-I, with TNFR-II receptor
acting as a carrier of TNFa to TNFR-I receptors. However, TNFR-II alone may
mediate TNFa-induced apoptosis in rhabdomyosarcoma 107 and Langerhans cell
• • 108
migration . Further, it has been suggested that TNFR-II receptors may mediate the
effects ofmembrane associated TNFa 109.
TNFR-I and TNFR-II also occur as soluble forms (sTNFR-I, sTNFR-II). These
soluble forms arise from the proteolytic cleavage of the extra-cellular domains of the
membrane-associated forms no. Although the exact mechanisms stimulating
membrane associated receptor cleavage are not clear, because receptor shedding
occurs after cell stimulation by TNFa, it has been suggested that receptor shedding
19
may be a mechanism through which cellular down-regulation can occur. However,
other biological effects may arise from the release of soluble TNF receptors.
Although soluble TNF receptors can bind free soluble TNFa thereby reducing the
bioactivity of TNFa 59' U1'112, binding may also act to stabilise homotrimeric TNFa
delaying its spontaneous decay 113. Therefore soluble TNF receptors may act as a
buffer of TNFa activity either prolonging or neutralising TNFa effects depending on
the prevailing TNFa conditions.
However, although the function of soluble TNF receptors is not clear, studies have
clearly demonstrated a relationship between the concentration of serum soluble TNF
receptors and the inflammatory process. In human experimental models of sepsis the
concentration of serum soluble TNF receptors correlates with peak levels of TNFa
following exposure to endotoxin 97, whilst infusion of recombinant TNFa leads to an
increase in circulating soluble TNF receptors 98. Serum sTNFR-I and sTNFR-II
concentrations are therefore considered to correlate with the degree of previous
exposure to TNFa. Similarly, clinical studies have demonstrated an association
between serum soluble TNF receptors concentrations and clinical outcome in
inflammatory states. In critical illness states, shedding ofmonocyte
membrane-associated TNF receptors is associated with increased disease severity
and adverse outcome 114, whilst concentrations of serum sTNFR-I and sTNFR-II
correlate with disease severity 69'115. Likewise, concentrations of serum soluble TNF
receptors correlate with disease severity in acute pancreatitis 91'95'96. Serum soluble
TNF receptor concentration may therefore be used as a measure of the inflammatory
response in critical illness states including acute pancreatitis.
20
Interleukin 1
The interleukin 1 family consists of 3 proteins; interleukin la (ILla), interleukin lp
(ILip) and interleukin 1 antagonist (IL1RA).
ILla and ILip are 17kDa proteins with 26% amino acid homology 116. ILla and
ILip are secreted primarily by cells of the monocyte/macrophage line although they
can be synthesised by most other nucleated cells 117. Both ILla and IL1 p bind to
interleukin 1 receptor type 1 and 2, but their effects are mediated solely through
interleukin 1 receptor type 1 (Table 5); interleukin 1 receptor type 2 binds interleukin
1 but does not transduce a signal 118. However, although their cellular effects are
broadly similar, differences in the pattern of expression may influence their
biological role. ILla is not readily secreted from the synthesising cell 119'120 but is
biologically active either as precursor ILla within the intracellular matrix, or
191
following processing as a membrane-associated protein . In contrast, IL1P exerts
• 199
its effect following extracellular secretion . These differences suggest that IL1 p
has a predominately systemic effect whilst ILla is primarily a regulator of local














Mediation of hepatic acute phase protein synthesis
Increased synthesis - C-reactive protein, complement, clottingfactors
Decreased synthesis - Albumin
Increased gene expression
Cytokines - TNF, IL1, 1L1RA, IL8
Pro-inflammatory mediators - cyclo-oxygenase, endothelin
Clottingfactors - fibrinogen, tissuefactor
Hepatic acute phase proteins - C-reactive protein, serum amyloid A
Adhesion molecules - L-selectin
Decreased gene expression
Receptors - TNF receptor type 1, IL1 receptor type 1
Table 5: The effects of interleukin 1 121.
IL1RA is a 22 to 25kDa protein the synthesis of which may be induced in most cells.
IL1RA demonstrates homology to ILla (18%) and IL1(3 (26%)I23'124 but in contrast
1 9 S •
is a pure antagonist of interleukin 1 receptor type 1 and 2 . The majority of active
IL1RA is extracellular but through the mechanism of intracellular gene splicing an
1 99
active intracellular form has been described
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A large number of agents can induce the synthesis of interleukin 1 (Table 6).
Considering both the nature of the agents able to induce IL1 secretion as well as the
effects of IL1 it would appear that the interleukin 1 family members are important
mediators of the inflammatory response. However, because of the potential for the
interleukin 1 family members to interact with each other as well as with both
membrane-associated and soluble interleukin 1 receptors, predicting their effects is
22
not straightforward. Both ILla and IL1 (3 may be antagonised by IL1RA at the
receptor level, whilst IL1(3 may interact with circulating soluble interleukin 1
receptors thereby buffering IL1 activity. This potential complexity may provide an
explanation for the observation that whilst improved outcome has been demonstrated
in animal models of sepsis following the administration of anti-interleukin 1






























Table 6: Agents which may induce the synthesis of interleukin 1 121.
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However, regardless of the potential complexity of the system, studies have
suggested that the interleukin 1 family has an important role in the mediation of
acute pancreatitis.
Up-regulation of ILip synthesis occurs within the inflamed pancreas mainly within
'77 1^1 1 T7 1 T7
leukocytes ' ' , and is accompanied by an increase in ILIRA synthesis
Concomitantly, increased ILip synthesis occurs in remote organs, and parallels the
• • 77
increase in systemic TNFa synthesis .
Again, manipulation of the mechanisms through which ILip is secreted and mediates
its effects, results in amelioration of disease severity in experimental models of acute
pancreatitis. Inhibition of interleukin 1 converting enzyme, which is required for
post-translational processing of ILip, results in a reduction in disease severity in an
experimental model of acute pancreatitis 133. Similarly, gene knockout of IL1
receptor 1 (IL1R-I) leads to a reduction in severity of experimental acute
oo i -34
pancreatitis ' , although levels of IL1 p mRNA increase suggesting the
involvement of IL1R-I in a negative feedback loop l3\ Finally the administration of
IL1RA in experimental models of acute pancreatitis reduces disease severity and
mortality 136"138.
These animal experimental studies have also demonstrated that a close interaction
occurs between ILip and TNF a in the mediation of acute pancreatitis. Inhibition of
interleukin 1 converting enzyme in acute pancreatitis results in a reduction in levels
of serum IL 1P but is also associated with a reduction in serum TNFa 133, whilst the
survival benefits of combined IL1R-I and TNFR-I gene knockout are greater than
IL1R-I or TNFR-I gene knockout in isolation 88.
However, despite the evidence regarding the role of ILip and IL1RA in the
pathogenesis of experimental acute pancreatitis there are few data available in
relation to human acute pancreatitis. Brivet and colleagues 89 observed that although
levels of serum IL1RA were raised in patients with severe acute pancreatitis, IL1P
could only be detected in the serum of 3 of 50 study subjects. Similarly McKay and
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colleagues 99 found no difference in IL1 (3 secretion from monocytes isolated from
patients during an episode ofmild or severe acute pancreatitis.
Interleukin 6
Interleukin 6 (IL6) is a member of the gpl30 signalling cytokine family. IL6 is
constitutively synthesised in the spleen, liver, kidney and intestinal tract and also by
peripheral leukocytes l39. Synthesis may however be induced in almost every cell
1TQ .... •
type following an appropriate stimulus . The role of IL6 in critical illness states is
not entirely clear. Although IL6 is a major mediator of the hepatic acute phase
protein response, it has also been demonstrated to have both pro-inflammatory and
anti-inflammatory effects l20'139"142. However, regardless of its exact role in the
pathogenesis of a systemic inflammatory response, IL6 production is correlated
closely with disease severity in acute pancreatitis.
A number of studies have reported that the concentration of serum IL6 is
significantly higher in patients with severe acute pancreatitis when compared to those
with mild disease 9I' 143"1475 and that IL6 levels precede the hepatic acute phase
protein response, as manifested by C-reactive protein concentrations, by 24 to 48
hours 9I'143'147. The source of the increased serum IL6 is not clear. In an
experimental animal model Norman and colleagues 77 suggested that IL6 synthesis
was confined to the pancreas, however McKay and colleagues 99 have reported that
monocytes isolated from patients with severe acute pancreatitis demonstrate
increased IL6 secretion when compared to patients with mild disease. Similarly de
Beaux and colleagues 100 have shown that IL6 production per unit of blood is
increased in patients with severe acute pancreatitis.
In summary, although relatively little is known regarding the pathogenic role of IL6
in acute pancreatitis the close correlation between serum IL6 and clinical outcome




Interleukin 8 is a pro-inflammatory chemokine secreted by a variety of cell types
The major effects of IL8 are upon neutrophils, stimulating chemotaxis, adhesion,
superoxide release and bacterial killing. Evidence is accumulating that IL8 plays an
important role in inflammatory conditions including acute pancreatitis. In patients
with acute pancreatitis serum concentrations of IL8 are significantly higher in
patients with severe disease when compared to those patients with mild
disease 145' 146'149>150_ Moreover serum concentrations of IL8 correlate with the
degree of organ dysfunction 151. The source of the increase in serum IL8
concentrations is not clear, however in patients with severe disease IL8 secretion by
monocytes is increased ", as is the secretion of IL8 per unit of blood 10°. Further
supporting the importance of IL8 in mediating the systemic effects of acute
pancreatitis is the observation that in an animal model of acute pancreatitis the
administration of an anti-IL8 antibody attenuated the cytokine response and reduced
• 152
acute lung injury but did not reduce the degree of pancreatic inflammation
Platelet Activating Factor
Platelet activating factor (PAF) is a lipid derived pro-inflammatory mediator that is
released from cell membrane lipids under the action of phospholipase A2. Studies
have suggested a role for PAF in the pathogenesis of acute pancreatitis. In an animal
model, the injection of PAF into the arterial blood supply to the pancreas provokes
lesions within the pancreas that are morphologically consistent with acute
pancreatitis 153. Further, following the induction of experimental acute pancreatitis,
PAF can be detected in both the pancreas and lung 154'155. Moreover, the
administration ofPAF antagonists result in the amelioration of both local pancreatic
injury 156-158 and remote organ injury 155'159' l6°. However, benefits derived from the
administration of a PAF antagonist in experimental models are not observed if
therapy is delayed until after the induction of acute pancreatitis 161. Interestingly
though, the administration of recombinant PAF-acetyl hydrolase, an enzyme
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involved in PAF degradation, after the induction of experimental acute pancreatitis
162resulted in the amelioration of the acute lung injury . These promising
experimental results have led to several randomised controlled trials assessing the
efficacy of the PAF antagonist lexipafant.
Kingsnorth and colleagues 163 demonstrated in a multicentre randomised controlled
trial involving 83 patients with acute pancreatitis, that lexipafant therapy was able to
ameliorate organ dysfunction and modulate serum IL8 concentrations. Similarly, a
significant improvement in organ dysfunction scores was observed following
lexipafant therapy in a randomised controlled trial of 50 patients with prognostically
severe acute pancreatitis presenting within 72 hours of disease onset 164. The final
study demonstrating potential benefit was a phase III multicentre randomised
controlled trial involving 290 patients with prognostically severe acute pancreatitis
who were randomised to receive either lexipafant for 7 days or placebo 165. When
analysed on an intention to treat basis there was no difference in mortality (24/139 vs
18/151, p=. 196), however subgroup analysis suggested a significant reduction in
mortality in those patients treated within 48 hours of disease onset (20/98 vs 11/107,
p=.04). Again lexipafant therapy led to significant improvements in organ
dysfunction scores and reductions in serum IL8 concentrations.
On the basis of these clinical trials a large multinational trial has been undertaken in
which patients were randomised to receive either high dose lexipafant, low dose
lexipafant or placebo. Although recruitment to the trial has now been completed,
formal publication of results is awaited. However, early reports suggest that




A number of cytokines have significant anti-inflammatory effects, and evidence is
accumulating to suggest that they have important roles in the pathogenesis of acute
pancreatitis.
Interleukin 10 (IL10) is an anti-inflammatory cytokine. Following induction of
experimental acute pancreatitis increased synthesis of IL10 mRNA can be observed
80in the pancreas, liver and lungs, paralleling increases in TNFa mRNA expression .
As may be predicted, evidence derived from experimental models appears to
suggests that IL10 has a protective role in acute pancreatitis. In animal models of
acute pancreatitis the administration of exogenous IL10 reduces the cytokine
response 166'167 and the systemic effects of acute pancreatitis 168'1 . Similarly,
transfection with a plasmid-human IL10 construct protected against the subsequent
initiation of acute pancreatitis in an animal model l70. Conversely interventions to
antagonise the actions of IL10 increase the severity of experimental acute
pancreatitis. The administration of anti-ILlO antibody increases the production of
TNFa and increases disease severity 166 whilst the elimination of IL10 through the
• 171
use of an IL10 gene knockout mouse also increases disease severity
However, although evidence from animal experimental models appears to confirm
that IL10 has a protective role in acute pancreatitis, evidence from human acute
•• ... **111 172
pancreatitis suggests that the situation is more complex. Pezzilli and colleagues
initially reported that serum concentrations of interleukin 10 were lower in patients
with severe acute pancreatitis when compared to those with mild disease, whilst
89Brivet and colleagues observed that serum concentrations of IL10 were lower in
non-survivors than survivors of an episode of severe acute pancreatitis. However,
other studies have observed increased levels of serum IL10 in patients with severe
disease 145,173, whilst a positive correlation between serum IL10 concentrations and
degree of organ dysfunction has also been observed 151.
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The explanation for these contrasting observations is not clear. Although initial
theories proposed that disease severity in critical illness states was due solely to
excessive pro-inflammatory mediators it is probable that an excessive
anti-inflammatory response is also detrimental. That is, outcome in critical illness
states may be the consequence of a complex interaction between pro-inflammatory
and anti-inflammatory mediators. Bone 76 has postulated the existence of a
compensatory anti-inflammatory response syndrome (CARS) which is a
consequence of the systemic inflammatory response and may help to perpetuate the
critical illness state by inducing a state of immunosuppression encouraging
opportunistic infection. In support of a complex interaction between
pro-inflammatory and anti-inflammatory cytokines is the observation of Simovic and
colleagues 174 that a decreased ratio of IL10 to IL6 or IL8 is important in determining
severe disease.
Further research is required to elucidate the importance of both pro-inflammatory
and anti-inflammatory mediators and their interaction in the pathogenesis of acute
pancreatitis.
Leukocytes
An important part of the current model of the pathogenesis of severe acute
pancreatitis is increased leukocyte activity. Both experimental and human
observational studies appear to support the concept of increased leukocyte activity in
severe acute pancreatitis.
A central role for neutrophils in the pathogenic mechanisms has been suggested by
neutrophil depletion experiments in animal models. Depletion of granulocytes
through the administration of hydroxyurea ameliorates the systemic effects of acute
• 17S
pancreatitis -. Likewise specific depletion of neutrophils through the
administration anti-neutrophil antibody reduces the local 176-178 and systemic 177-179
effects in experimental models of acute pancreatitis. It should however be noted that
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neutrophil depletion did not affect local pancreatic inflammation in a canine model
• 180
of acute pancreatitis
Studies in human patients would appear to confirm increased neutrophil activity in
acute pancreatitis. Leukocyte scintigraphy has demonstrated increased uptake in the
pancreas in patients with severe disease confirming localisation of activated
181 •
leukocytes within the pancreas . Similarly, several studies have confirmed
increased activation of circulating neutrophils in patients with severe acute
pancreatitis when compared to those with mild disease as evidenced by increased cell
adhesion and superoxide production l42, increased neutrophil fluorescence with
• 189 • 18T
acridine orange and luminol-enhanced chemoluminescence . However,
although increased neutrophil phagocytic activity has been reported l42, impaired
phagocytosis has also been reported l82. Further evidence of increased leukocyte
activation in severe acute pancreatitis comes from the observation that patients with
severe disease have significantly greater levels of serum polymorphonuclear elastase
• 184
than those with mild disease
Monocyte function in acute pancreatitis has also been studied. Isolated monocytes
from patients with severe acute pancreatitis demonstrate increased secretion of
TNFa, IL6 and IL8 ", although cytokine secretion by peripheral blood mononuclear
cells (monocytes and lymphocytes combined) is not increased I0°. In contrast
however, other studies have suggested reduced monocyte function in severe acute
• • • 18S •
pancreatitis. Larvin and colleagues demonstrated that monocyte phagocytic
function was reduced in patients with severe acute pancreatitis. Similarly Richter
1 86
and colleagues demonstrated down-regulation ofmonocyte human leukocyte
antigen DR (HLA-DR) expression in those with severe disease, the suppression
being greatest in those that died. The observations of decreased phagocytic function
and HLA-DR expression would appear to further support the growing body of
evidence that a compensatory anti-inflammatory response is important in
determining outcome in acute pancreatitis.
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Finally although a few studies have examined lymphocyte counts in acute
pancreatitis, little is known regarding changes in function. In patients with severe
acute pancreatitis there is a reduction in both the total lymphocyte count and the
CD4+ lymphocyte count183'187'188, although the CD4+:CD8+ ratio is maintained 183.
Endothelial Cells
Because of their relative inaccessibility the study of endothelial cell function in acute
pancreatitis is difficult. Although direct evidence of endothelial cell activation in
acute pancreatitis is available from studies in animal models, what little evidence that
exists from human acute pancreatitis is indirectly determined through the
measurement of serum soluble endothelial cell-derived molecules.
Intercellular Adhesion Molecule-1
Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein
• • • 180
belonging to the immunoglobulin gene superfamily . In the normal
(non-activated) state, endothelial cells demonstrate low levels of ICAM-1 cell
surface expression, however following cellular activation expression is dramatically
up-regulated. TNFa, ILlp, interferon y and endotoxin are potent stimuli for
endothelial ICAM-1 expression. Endothelial ICAM-1 cell surface expression is
important in leukocyte-endothelial interactions during acute inflammation, enabling
• 1RQ
the endothelial cell to bind to leukocyte cell surface integrins
Recent studies have suggested a role for ICAM-1 in the mediation of organ
dysfunction in severe acute pancreatitis. Although an initial study did not observe an
increase in pulmonary endothelial cell expression of ICAM-1 in an experimental
model of acute pancreatitis 190, further studies have demonstrated that increased
178 1Q1 1Q9
pulmonary ICAM-1 does occur ' ' , following increased pancreatic ICAM-1
expression 191. The precise mechanisms through which ICAM-1 expression is
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up-regulated in acute pancreatitis is not known, although both TNFa , and oxygen
free radicals have been implicated 190. Importantly, interventional studies aimed at
blocking the action of ICAM-1 have suggested that up-regulation of ICAM-1
expression is a major event in the mediation of acute pancreatitis. The
administration of a monoclonal antibody to ICAM-1 reduces both the local 191'194'195
and systemic effects of acute pancreatitis 191'1 '1 5'196. Further, disease severity is
less when acute pancreatitis is induced in mice that are deficient in ICAM-1 178. This
improvement in outcome would appear to be the result of a perturbation of the
leukocyte-endothelial cell interaction resulting in improved capillary blood flow,
reduced leukocyte rolling, and stabilisation of capillary permeability 195.
Few data exist regarding the role of ICAM-1 in human acute pancreatitis although
those which do are in concordance with observations derived from experimental
models. Kaufmann and colleagues 197 have demonstrated that levels of serum
ICAM-1 are significantly higher in patients with severe acute pancreatitis when
compared to those with mild disease.
Selectin Family
The selectin family of cell adhesion molecules have an important early role in
leukocyte margination and adhesion. The family consists of 3 related cell surface
molecules; L-selectin, P-selectin and E-selectin, of which P-selectin and E-selectin
• 1QS
are expressed on endothelial cells following an inflammatory stimulus
A differential pattern of endothelial selectin expression appears to exist. P-selectin is
stored pre-formed as a membrane component of the endothelial cell Weible-Palade
body 199 and demonstrates rapid surface expression following cell stimulation by
various agonists (e.g. thrombin, histamine, complement fragments 20°). In addition
de-novo synthesis of P-selectin occurs following endothelial cell stimulation by
various pro-inflammatory mediators including tumour necrosis factor-a, interleukin
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IP and lipopolysaccharide 20In contrast E-selectin is not stored pre-formed in
endothelial cells but is synthesised de-novo following an inflammatory stimulus (e.g.
909 901
TNFa, ILip and lipopolysaccharide ' ). As a consequence of this requirement
for synthesis, E-selectin cell surface expression lags behind P-selectin cell surface
expression. Following cell surface expression, the interaction of P-selectin and
E-selectin with their respective ligands on the cell surface of neutrophils and
monocytes leads to leukocyte rolling and capture, the first steps in leukocyte
migration 198. Down-regulation of both P-selectin and E-selectin surface expression
occurs mainly through internalisation 204>2055 however release of soluble forms of
OfiO on/i *)(\H
E-selectin and P-selectin also occurs ' ' . These soluble forms of selectins can
be measured in serum and may therefore be markers of endothelial cell
activation 208'209.
Evidence is accumulating from experimental models that suggests that the selectin
family of adhesion molecules play important roles in acute pancreatitis.
Elp-regulation of P-selectin occurs within the lung following the induction of
experimental acute pancreatitis 190'210. Interestingly, Lundberg and colleagues 210
observed a biphasic expression of P-selectin within the lung with the second peak
coinciding with maximal E-selectin expression at 48 hours, and have suggested that
the second P-selectin peak and the delayed E-selectin peak is mediated by
pro-inflammatory cytokines. Finally the administration of an anti-P-selectin
antibody ameliorates the acute lung injury in experimental acute pancreatitis l9°.
In summary, data derived from both experimental animal models and from patients
with acute pancreatitis would appear to support the hypothesis of a systemic
inflammatory response characterised by the secretion of inflammatory mediators, the
activation of leukocytes and their interaction with activated endothelial cells.
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Immunogenetics of TNF and IL1
Tumour Necrosis Factor Gene Locus
The genes for both TNFa and TNFp are located on the short arm of chromosome 6
and are closely associated with the major histocompatibility complex. Within the
2iiTNF gene locus a number of polymorphisms have been described (Figure 1).
Three restriction length polymorphisms (RFLP) have been described within the
TNFp gene (Ncol\ AspUl and £coRI). Further, two single base polymorphisms in
the promoter region of TNFa gene at positions -238 and -308 have been described.
Finally, 5 microsatellites consisting of a variable copy number of dinucleotide
repeats have also been described across the TNF gene locus.
TNF-308
A guanosine (G) to adenosine (A) base substitution may occur at position -308 of the
919.
TNFa promoter region giving rise to two possible alleles (Figure 1 polymorphic
site 4). The uncommon A base substitution has been designated as allele 2. Because
of the position of the polymorphism within the promoter region of the TNFa gene it
has been suggested that this polymorphism may have functional significance.
9 1 T
Wilson and colleagues have demonstrated that position -308 is the site of
interaction for a DNA binding protein. Further, through the use of a plasmid
mediated transient transfection system they demonstrated that allele 2 was associated
with increased TNFa secretion, but was not associated with altered affinity for the
DNA binding protein 2I3. Likewise, Kroeger and colleagues 214 using a similar
transfection system confirmed that the A base substitution was associated with an
increase in TNFa production, however they observed differential affinity for DNA
binding proteins within the 38 base pair region encompassing position -308. Further,
9 1 c
Louis and colleagues demonstrated that the uncommon A base substitution is
associated with increased TNFa secretion in a whole blood culture system following
34
• • • • 216*
lipopolysaccharide stimulation. However, Brinkman and colleagues did not
observe differential secretion ofTNFa between the two alleles within a transient
transfection system. More recent data has however suggested that differential TNFa
secretion associated with the TNF-308 polymorphism is both cell and stimulus
specific 217.
Although laboratory studies demonstrate an association between TNF-308 genotype
and TNFa secretory phenotype, it is more significant that studies have demonstrated
an association between TNF-308 genotype and outcome in cytokine-mediated acute
inflammatory conditions. In children with meningococcal disease TNF-308 allele 2
218is associated with increased disease severity and an increased risk ofmortality
Similarly TNF-308 allele 2 is associated with an increased risk of death or severe
9 1Q
neurological sequelae in children suffering from malaria . Further, in a
multicentre observational study involving critically ill patients, carriage of TNF-308
• 220allele 2 was associated with increased susceptibility to septic shock ; moreover,
when controlled for other potential risk factors, carriage of TNF-308 allele 2 was
associated with a 3.7 fold increased risk of death (95% C.I. 1.37 to 10.24) 220.
TNF-238
A guanosine (G) to adenosine (A) base substitution may occur at position -238 of the
221 • •TNFa promoter region giving rise to two possible alleles (Figure 1 polymorphic
site 3). The uncommon A base substitution has been designated allele 2. The
functional effects of this polymorphism are not clear. Recently Kaluza and
222 •
colleagues using a luciferase reporter gene assay demonstrated that allele 2 is
associated with reduced production of TNFa. This is in contrast to previous in vitro
studies which did not demonstrate an association between TNF-238 genotype and
TNFa phenotype 223"225. However, although the relationship between TNF-238
genotype and cytokine secretion is not clear, associations between the carriage of
TNF-238 allele 2 and susceptibility to alcoholic steatohepatitis226, chronic active
hepatitis C 227 and hepatitis B infection 228 have been described. TNF-238 genotype
is however not associated with disease severity in meningococcal disease 225.
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TNFB
Within the first intron of the TNFP gene an Ncol restriction fragment length
polymorphism exists 229 (Figure 1 polymorphic site 7). This polymorphism has been
correlated with an amino acid variation within the TNFp sequence at position 26.
Phytohemagglutinin stimulated peripheral blood mononuclear cells from individuals
homozygous for allele 1 demonstrate increased secretion of TNFa, whilst
phytohemagglutinin and endotoxin stimulated monocytes from individuals
229 232
homozygous for allele 2 demonstrate increased secretion of IL1P and TNFp " .
However, despite poor association between TNFB genotype and cytokine secretory
phenotype in isolated cell culture, significant associations between TNFB genotype
and disease severity in critically ill patients have been described. In an observational
study consisting of 40 patients with a diagnosis of sepsis, Stuber and colleagues
found that patients who were homozygous for TNFB allele 2 had increased levels of
circulating TNFa. Further, those homozygous for allele 2 had significantly higher
organ dysfunction scores and a significantly increased mortality rate. In a further
study the same research group observed that following major trauma patients
homozygous for TNFB allele 2 were at significantly higher risk of developing sepsis
than patients with other TNFB genotypes 234.
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Interleukin 1 Family Gene Locus
The genes for all three members of the interleukin 1 family are located on the long
arm of chromosome 2 239 and are thought to arise from a common ancestral gene 121.
A number of polymorphisms have been described within the gene locus (Figure 2).
Given that research has focussed mainly on the role ofIL1p and IL1RA in the
development of the systemic inflammatory response, consideration will be given to
the polymorphisms within the ILip and IL1RA gene loci which may give rise to
phenotypic differences.
Interleukin ip
Two polymorphisms have been described within the interleukin ip gene (Figure 2).
Interleukin 1P -511
The first polymorphism consists of a cytosine (C) to thymine (T) base substitution at
position -511 in the IL1 p gene promoter region giving rise to two potential alleles 240
(Figure 2 polymorphic site 7). To date no studies have directly examined the effects
of this polymorphism upon IL1P gene transcription. However, there does not appear
to be a direct correlation between ILip -511 genotype and serum ILip in healthy
individuals, although Hulkkonen and colleagues have suggested that an interaction
exists between ILip -511 genotype and an ILla polymorphism which correlates
with increased serum ILip concentrations 24'. A further association has been
described between ILip -511 allele 2 and allele 2 of the IL1RA gene variable
number tandem repeat polymorphism 242.
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Interleukin 1(3 Taql
The second polymorphism consists of a Taql restriction fragment length
polymorphism and occurs in exon 5 of the IL1 (3 gene 243 (Figure 2 polymorphic site
6). This arises as a consequence of a cytosine (C) to thymine (T) single base
variation and gives rise to the potential for 2 alleles. The Taql polymorphism occurs
in allele 1 and is the more common allele. The functional effects of the
polymorphism are not entirely clear, although Pociot and colleagues 243 demonstrated
increased secretion of IL1(3 by stimulated monocytes in individuals carrying allele 2.
Similarly Wilkinson and colleagues 244 have demonstrated increased monocyte IL1(3
mRNA expression in individuals with carriage of allele 2 following stimulation with
mycobacterium tuberculosis. However, carriage of IL 1P Taql allele 2 occurs less
frequently in carriers of allele 2 of the IL1RA gene variable number tandem repeat
polymorphism 242. Therefore potential secretory differences may not be directly
attributable to the interleukin 1(3 Taql polymorphism, rather they may be related to
IL1RA gene polymorphism. Regardless the IL 1 (3 Taql polymorphism has been
associated with clinical outcome in inflammatory bowel disease 245'246, multiple
sclerosis 247 and alcohol-induced liver disease 248.
Interleukin 1 Receptor Antagonist
The gene locus for interleukin 1 receptor antagonist has been designated IL1RN.
Two polymorphisms exist within the IL1RN gene locus (Figure 2).
IL1RN (VNTR)
An 86 base pair variable number tandem repeat sequence exists in intron 2 of the
IL1RN gene 249 (Figure 2 polymorphic site 11). Previous studies have identified the
potential for 5 different alleles of which allele 2 is associated with increased IL1RA
secretion 242' 25°. Although the mechanism through which this polymorphism
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influences IL1RA secretion is not clear, a large number of studies have suggested
that IL1RN (VNTR) allele 2 is associated with disease susceptibility and severity in a
number of inflammatory conditions 25 '~255.
IL1RN (+2016)
A single base cytosine (C) to thymine (T) base substitution may occur at position
+2016 within exon 2 giving rise to two potential alleles 256 (Figure 2 polymorphic
site 10). These two alleles are in 100% linkage disequilibrium with the two most
frequent alleles of IL1RN (VNTR) - allele 1 and allele 2. No studies have examined























































Critical Illness And The Intestinal Tract
The intestinal tract has many functions which are often interrelated and which may
appear contradictory. For example, although the major role of the intestinal tract is
the digestion and absorption of nutrients, it must also be both a physical and
immunological barrier to molecules and organisms which if allowed to cross from
the intestinal lumen could provoke a disease process. It is the failure of this
intestinal barrier function which has been hypothesised to promote and sustain the
systemic inflammatory response syndrome 264.
It has been hypothesised that a reduction in intestinal motility, altered intestinal
microflora and failure of intestinal barrier function allow bacteria and, or, bacterial
products to transfer from the intestinal lumen to the circulation 264. This process has
been termed bacterial translocation. Although the potential exists for a large number
of bacteria or bacterial products to translocate, research has focussed on the role of
endotoxin in the pathogenesis of the systemic inflammatory response. Endotoxin is a
lipopolysaccharide derived from the outer membrane of gram-negative bacteria and
has been demonstrated to be a potent pro-inflammatory stimulus. Other potential
stimuli do exist; both peptidoglycan, a polysaccharide derived from gram-positive
bacteria, and bacterial DNA can provoke a systemic inflammatory response 265.
Intestinal Permeability
Although intestinal function in critical illness can be relatively easily studied in
animal models, it is necessarily more problematic in human patients, therefore
indirect techniques for the assessment of intestinal function have been derived. One
such method is the determination of intestinal permeability which may in turn be
used as a surrogate marker of intestinal barrier function 266'267. Intestinal
permeability relates to the passage of a solute across the intestinal epithelium through
non-mediated diffusion. This is in contrast to absorption which is carrier-mediated.
In any given state, permeability is dependent on the structure of the membrane, the
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physicochemical properties of the solute and its interaction with the solvent. This
therefore means that changes in intestinal barrier function occurring during critical
illness states can be quantified by determining intestinal permeability through the
measurement of the uptake of standardised non-metabolised probes. In practice,
intestinal permeability is assessed by measuring the urinary excretion of orally
administered test probes.
For the determination of intestinal permeability the perfect theoretical probe should
be water-soluble, have first-order kinetics of permeation, be non-toxic,
non-degradable and not metabolised either before, during or after permeating the
intestinal tract. In addition because the tests rely on the quantification of the probe in
urine following excretion, the probe should not be naturally present in urine, urinary
excretion should be the sole mechanism of loss and urinary excretion should be
complete following intravenous administration. Moreover measurement of the probe
should be easy, sensitive and accurate.
Intestinal permeability is therefore quantified through a timed collection of urine
following the ingestion of a fixed quantity of probe. Because other factors such as
gastric emptying, intestinal blood flow and renal perfusion have the potential to
confound the kinetics of the urinary excretion of the ingested probe, two probes are
administered and it is the differential urinary excretion of these probes that is
calculated in order to determine intestinal permeability 266'267. Although a number of
probes have been used it is conventional to use a monosaccharide and a disaccharide
together.
Critical Illness States And Changes In Intestinal Permeability
A number of studies have confirmed that, as postulated, intestinal barrier function is
altered during the systemic inflammatory response.
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O'Dwyer and colleagues demonstrated that increased intestinal permeability
occurs in a human experimental model of the systemic inflammatory response
syndrome. Following the systemic administration of endotoxin to 12 healthy
volunteers an increase in intestinal permeability to lactulose and mannitol was
observed, with the degree of intestinal dysfunction correlating with the degree of
systemic perturbation as manifested by serum norepinephrine concentration and
white blood cell count.
Similar changes in intestinal permeability have been observed in critically ill
patients. Johnston and colleagues observed increased intestinal permeability to
lactulose and rhamnose in 20 patients with sepsis when compared to healthy
970 • • •
individuals. Likewise, Flarris and colleagues demonstrated increased intestinal
permeability to lactulose and mannitol in 16 critically ill patients, although there did
not appear to be any correlation between intestinal permeability and disease severity.
Finally Ziegler and colleagues 271 reported that patients with infected burns
demonstrated increased intestinal permeability to lactulose and mannitol correlating
with the severity of the burn infection. Interestingly patients with simple
non-infected burns did not have increased intestinal permeability.
It would therefore appear that the development of a systemic inflammatory response
syndrome is associated with increased intestinal permeability. However, it should be
noted that studies assessing intestinal permeability in critical illness do not provide
direct evidence regarding the role of the intestinal tract in sustaining the systemic
inflammatory response, that is, it is not clear whether the changes observed in the
intestinal tract are solely a manifestation of the systemic inflammatory response or
whether the changes are important in mediating the disease process itself.
Effects Of Enteral Nutrition On Intestinal Permeability
The mechanisms through which intestinal dysfunction arises in critical illness states
are not clear, although a number of factors have been postulated. These factors
44
include splanchnic ischaemia/reperfusion, sepsis, therapeutic intervention and loss of
enteral nutrition 272. Unfortunately not all of these factors can be easily modified by
the treating clinician, however because of the potential for relatively simple
intervention, it is the loss of enteral nutrition which deserves special attention.
In an observational study involving healthy volunteers and malnourished patients,
77-3
Maxton and colleagues observed that starvation for a period less than 36 hours did
not increase intestinal permeability but did reduce intestinal absorption, whilst longer
periods of starvation increased intestinal permeability and reduced intestinal
absorption. However, the alteration in intestinal permeability does not appear to be
due solely to the loss of adequate nutrition. Buchman and colleagues 274 observed
that healthy individuals maintained on parenteral nutrition instead of normal enteral
nutrition also demonstrated increased intestinal permeability. These observations
together suggest that in order to maintain normal intestinal function adequate
nutrition needs to be provided by the enteral route. It would therefore seem logical
that as part of any therapeutic management strategy designed to minimise intestinal
dysfunction in critical illness states, adequate nutrition should be delivered through
the enteral route.
However, only a few randomised clinical trials have examined the effect of enteral
nutrition upon intestinal dysfunction in critical illness states. Hadfield and
97S ...
colleagues ' assessed the benefit of enteral nutrition in maintaining normal
intestinal function in patients with a critical illness. In total 24 patients were
randomised to receive either enteral or parenteral nutrition. At the start of the trial
intestinal permeability was increased in both groups. However, by day 9 a
significant reduction in intestinal permeability was observed in the group receiving
enteral nutrition, whilst no change in intestinal permeability was observed in those
receiving parenteral nutrition.
Further, in a randomised trial involving 30 patients undergoing elective laparotomy
and intestinal resection, when compared to standard care with intravenous
crystalloid, the introduction of enteral nutrition in the immediate post operative
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period was associated with maintained intestinal permeability . However, in a
similar randomised trial involving patients undergoing elective resection of upper
977
gastro-intestinal malignancy, Brooks and colleagues found that intestinal
permeability was increased on the first post-operative day in all patients and returned
to normal on the fifth post-operative day irrespective of whether they did or did not
receive enteral nutrition.
In summary, published studies examining the effect of the administration of enteral
nutrition upon intestinal permeability in critical illness states are inconclusive.
However, regardless of the effects of enteral nutrition on markers of intestinal
function such as intestinal permeability, changes in disease mortality and morbidity
are the most important outcome measures. Therefore evidence of improved clinical
outcomes must come from well constructed randomised trials before it can be
conclusively stated that the delivery of nutrition via the enteral route is required in
order to provide the optimum outcome in patients with a critical illness.
Trials Of Enteral Nutrition In Critical Illness
To date a large number of trials have been undertaken in an attempt to assess the
potential benefit of enteral nutrition in patients with trauma, burns, critical illness
states or following elective gastro-intestinal surgery (Table 7 and Table 8). Although
the majority appear to suggest that enteral nutrition provides significant benefit,
methodological differences and flaws may be identified within and between
published trials with the result that definite conclusions may not be drawn.
Firstly the majority of published trials contain relatively few study subjects thereby
rendering the trials statistically under-powered. Secondly in some trials the
• 278nutritional regimes administered to each randomised group were not isocaloric or
isonitrogenous 278"282. Thirdly the methods of nutritional support were not consistent
between trials, with comparison between enteral nutrition and parenteral nutrition as
978 970 989 988
well as enteral nutrition and the fasting state . Finally the enteral
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nutrition formulation under investigation is not consistent between trials, with more
recent studies employing supplemented nutritional formulae which have been
promoted to have immune-enhancing properties with proposed further improvement
in clinical outcome 278-282>285"287_
In an attempt to circumvent these difficulties, several groups have carried out
meta-analysis of published enteral nutrition trials.
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The first meta-analysis was carried out by Moore and colleagues and included
data derived from two published randomised trials and six previously unreported
randomised trials all ofwhich were designed to assess the benefit of enteral nutrition
when compared to parenteral nutrition in surgical patients. In total, outcome data for
230 patients who had undergone both elective and emergency surgery were
available. When analysed on an intention-to-treat basis, patients receiving enteral
nutrition had significantly fewer infectious complications (16% enteral vs 29%
parenteral p=.03), with the greatest benefit occurring in patients with major trauma.
Likewise Heys and colleagues 290 carried out a meta-analysis of 11 published
randomised trials assessing the beneficial effects of immune-enhancing enteral
nutrition when compared to standard enteral nutrition. The subsequent analysis of
data derived from 1009 patients demonstrated that the use of an immune-enhancing
diet was associated with a significant reduction in major infectious complications,
that is pneumonia, major wound infection, intra-abdominal collection and
septicaemia (odds ratio 0.47, 95% CI 0.32 to 0.70). However, although there was no
significant difference between the two patient groups with respect to mortality, there
was a trend to increasing mortality in those patients receiving supplemented enteral
nutrition (OR 1.77 95% CI 1.00 to 3.12).
Similarly Beale and colleagues 291 carried out a meta-analysis of twelve published
studies assessing the benefits of supplemented enteral nutrition formulae. Eight of
these twelve studies were included in the meta-analysis carried out by Heys and
colleagues 29°. Beale analysed outcome data derived from 1,482 patients who had
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been randomised to either standard enteral nutrition or a supplemented
(immune-enhancing) nutritional formula. On an intention-to-treat basis,
immune-enhancing nutritional formulae were associated with a significant reduction
in septic complications (OR 0.60 95% CI 0.28 to 0.83) and a significant reduction in
the number of days of ventilation (2.6 days reduction 95% CI 0.1 to 5.1). However,
immune-enhancing nutrition was not associated with an improvement in the
mortality rate (OR 1.05 95% CI 0.78 to 1.41).
Overall, results from published trials suggest that enteral nutrition is associated with
a significant reduction in infectious complications, although as yet there is no
definite evidence demonstrating that this results in a reduction in mortality.
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The Intestinal Tract In Acute Pancreatitis
As with other organ systems, the intestinal tract is affected early in the course of
acute pancreatitis. However, it would appear that the intestinal tract is not merely a
bystander in the pathogenesis of severe disease, rather evidence is accruing to
implicate intestinal tract dysfunction as a major factor in maintaining the systemic
inflammatory response which characterises severe acute pancreatitis.
Alterations In Intestinal Tract Function In Experimental Acute
Pancreatitis
The majority of data relating to the intestinal tract in acute pancreatitis have been
obtained from animal models, although data do exist relating to human acute
pancreatitis and this is in concordance with the animal model-derived evidence.
During the early stages of experimental acute pancreatitis, intestinal blood flow is
reduced " , to the extent that in severe disease splanchnic hypo-perfusion results
JQO
in both mucosal and subserosal ischaemia . It is likely that this period of
ischaemia along with the subsequent reperfusion injury is a major factor in initiating
• • 272intestinal tract dysfunction
Following the initial insult, the interval between migrating myoelectric complexes
increases 299 resulting in decreased intestinal motility and increased intestinal transit
time 300>301. This decrease in intestinal motility allows for an alteration of the
intestinal microflora and colonisation of the normally sterile upper intestinal tract
TOO TOT .... . .
with bacteria ' . In addition, intestinal epithelial cell dysfunction occurs
resulting in failure of intestinal barrier function. This failure of intestinal barrier
function is in part manifested by an increased permeability to non-absorbable
molecules 291, the increase in which is correlated with the severity of the acute
TOT
pancreatitis . Accompanying the increase in intestinal permeability to
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non-absorbable molecules there is a reduction in the normal active transport of other
9Q7
molecules
Effects Of Intestinal Tract Dysfunction In Experimental Acute
Pancreatitis
It has been hypothesised that a reduction in intestinal motility, altered intestinal
microflora and failure of intestinal barrier function allow bacteria and/or, bacterial
products to transfer from the intestinal lumen to the circulation 264. This process has
been termed bacterial translocation, and has been proposed to be important in
maintaining a systemic inflammatory response. However, in acute pancreatitis
translocation of bacteria from the intestinal tract may have consequences other than
the maintenance of a systemic inflammatory response. Evidence has accumulated
that the intestinal tract is the origin of organisms involved in the development of
infected pancreatic necrosis complicating acute pancreatitis 304.
The process of bacterial translocation is relatively easily studied in animal models of
acute pancreatitis, with culture of tissue including mesenteric lymph nodes allowing
quantification of bacterial translocation. Many studies have confirmed the process of
bacterial translocation in experimental acute pancreatitis 300"302'305-306, and its
association with decreased intestinal motility 300'301 and altered intestinal
microflora 300'302.
It is most probable that bacterial translocation to mesenteric lymph nodes occurs
through the intestinal lymphatic system, but the routes through which bacteria spread
T07 T08
from the intestinal tract to the pancreas are less clear . Medich and colleagues
demonstrated spread of fluorescent beads from the gut to the pancreas through the
transperitoneal route. In contrast, Arendt 309 suggested that the peritoneal cavity
acted as a barrier to transperitoneal spread. However, in a series of experiments
Tin
Widdison and colleagues have demonstrated that colonisation of pancreatic
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necrosis can occur through haematogenous spread, transperitoneal spread or
retrograde spread along the pancreatic duct.
Further evidence supporting the importance of the intestinal tract in the pathogenesis
of infected pancreatic necrosis comes from experiments assessing the effects of
•• •• •• Til
intestinal decontamination. Foitzik and colleagues demonstrated that oral
antibiotics altered normal intestinal flora and when combined with intravenous
antibiotics led to a reduction in rates of pancreatic infection. Similarly in a mouse
model of severe acute pancreatitis, therapy with oral bacitracin, metronidazole and
neomycin resulted in reduced rates of positive bacterial cultures from samples of
in
peripheral blood, ascites, spleen and pancreas. Further, Gianotti and colleagues
evaluated several different gut decontamination regimes in a mouse model of acute
pancreatitis. Although all decontamination regimes resulted in significant reductions
in intestinal bacterial flora, not all regimes were associated with decreased rates of
bacterial translocation and reduced mortality rates, suggesting that the benefits of gut
decontamination do not arise solely from the elimination of pathogenic intestinal
bacteria. Finally, simple colonic lavage has been demonstrated to reduce bacterial
1 o
translocation in a rat model of acute pancreatitis
The Intestinal Tract In Human Acute Pancreatitis
In human acute pancreatitis, direct assessment of splanchnic blood flow is difficult.
Using a regional catheter and dilution dye technique, Ruokenen and colleagues 314
demonstrated that following fluid resuscitation splanchnic blood flow in patients
with severe acute pancreatitis is similar to that in patients prior to elective major
abdominal surgery. Flowever, splanchnic oxygen consumption was significantly
increased in patients with severe acute pancreatitis suggesting that despite
maintained splanchnic blood flow, oxygen delivery may not be sufficient.
Further data relating to intestinal perfusion in acute pancreatitis is derived from the
use of intestinal pH manometry. During episodes of intestinal hypoperfusion the
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intra-mucosal pH falls and this may be measured providing indirect evidence of
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intestinal ischaemia. Juvonen and colleagues demonstrated a fall in gastric
intra-mucosal pH within the first 48 hours of presentation in all patients with acute
pancreatitis, but did not observe significant differences in intra-mucosal pH between
patients with mild or severe disease. In contrast Soong and colleagues 96 observed
significantly lower gastric intra-mucosal pH measurement in patients with severe
acute pancreatitis when compared to those with mild disease. Similarly within the
group of patients with severe acute pancreatitis, prolonged falls in intra-mucosal pH
correlates with poor outcome l51'316.
In addition to alterations in intestinal perfusion, patients with severe acute
pancreatitis demonstrate increased intestinal permeability. Ammori and
T i 7 t
colleagues quantified intestinal permeability using polyethyleneglycol (PEG) 400
and PEG 3350. Using this technique Ammori demonstrated increased intestinal
permeability in patients with severe acute pancreatitis. Moreover the increase in
intestinal permeability correlated with the presence of organ dysfunction. Further, an
association existed between increased intestinal permeability and endotoxaemia, an
observation in keeping with the concept of bacterial translocation.
Other studies have also examined the presence of endotoxaemia in acute pancreatitis.
Foulis and colleagues 318 were the first to observe that endotoxaemia occurs more
frequently in patients with severe acute pancreatitis than those with mild disease,
their results subsequently being confirmed 92'96. However, endotoxaemia is not
observed to occur in all cases of severe acute pancreatitis 92'96'151'318 and therefore it
has been suggested that endotoxaemia may be transient and consequently missed by
intermittent sampling. As a result serum anti-endotoxin antibody concentrations
have been proposed as an indirect measure of endotoxin exposure. Windsor and
Tin
colleagues observed that a significant fall in the serum anti-endotoxin core
antibody class IgG concentration was associated with severe disease, whilst Soong
and colleagues 96 demonstrated that a fall in anti-endotoxin core antibody class IgM
concentration was associated with poor outcome. Falls in serum anti-endotoxin core
antibody concentrations would be in keeping with consumption of endogenous
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antibodies following exposure to endotoxin exposure and would again support the
concept of bacterial translocation.
Further evidence demonstrating the importance of the intestinal tract in the
pathogenesis of severe acute pancreatitis is provided by a randomised controlled trial
assessing the benefit of selective gut decontamination in patients with severe acute
• ^90
pancreatitis. In a multicentre trial, Luiten and colleagues randomised 102 patients
with prognostically severe acute pancreatitis as defined by multiple laboratory
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criteria (Glasgow ) and/or contrast enhanced-CT scoring (Balthazar ) to either
standard conventional therapy or standard conventional therapy supplemented with
selective gut decontamination using oral and rectal colistin, amphotericin and
norfloxacin. In addition, patients in the selective gut decontamination group received
intravenous cefotaxime until aerobic gram negative bacteria were eliminated from
the oral cavity and rectum as determined by serial bacterial culture Although there
was a reduction in mortality from 35% in the control group to 22% in the selective
decontamination group it did not reach significance (p=.19). However, when
allowing for differences in disease severity, multivariate analysis suggested a
significant survival benefit following gut decontamination (p=.048). Encouragingly
selective gut decontamination reduced rates of pancreatic infection when compared
to the control group (38% vs 18%, P=.03). Further, re-colonisation of the intestinal
tract by gram negative bacteria following the implementation of the selective gut
decontamination regime was a significant risk factor for the subsequent development
999
of pancreatic infection by the same organism
Enteral nutrition in acute pancreatitis
Part of the accepted management of acute pancreatitis is the institution of a
nil-by-mouth regime. Prior to the newer models of acute pancreatitis it had been
hypothesised that organ dysfunction in acute pancreatitis was due to the systemic
action of activated digestive enzymes released into the circulation from the inflamed
pancreas. Fasting was therefore believed to limit detrimental pancreatic secretion.
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However, given the current hypotheses regarding the role of the systemic
inflammatory response in mediating organ dysfunction in acute pancreatitis and the
putative importance of intestinal tract dysfunction in maintaining this inflammatory
response, the rationale for the nil-by-mouth regime has been challenged. It is
significant therefore, that the introduction of enteral nutrition would appear to
reverse the changes that have been postulated to be important in maintaining the
systemic inflammatory response in acute pancreatitis. In an animal model of acute
pancreatitis, Kotani and colleagues 324 demonstrated that when compared to
parenteral nutrition the introduction of enteral nutrition maintains intestinal villus
height and enterocyte cell proliferation, maintains lymphocyte function and
decreases bacterial translocation as manifested by mesenteric lymph node cultures
and systemic plasma endotoxin concentration. However, although these observations
would appear to be consistent with recent hypotheses and suggest significant benefit,
before it can be definitively concluded that the use of enteral nutrition in acute
pancreatitis provides significant clinical outcome benefits, evidence from randomised
clinical trials is required. Importantly therefore, three small randomised clinical
trials have recently been published which provide an early assessment of the benefits
of enteral nutrition in acute pancreatitis.
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McClave and colleagues randomised 30 patients with acute pancreatitis to receive
either early enteral nutrition through an endoscopically placed nasojejunal feeding
tube, or, parenteral nutrition following central or peripheral venous cannulation.
Enteral nutrition appeared to be well tolerated with no patients developing a
significant complication from the study intervention. Importantly enteral nutrition
was able to supply a similar calorific intake to parenteral nutrition. However,
patients had relatively mild disease and thus no significant differences in clinical
outcome were observed, although enteral nutrition was associated with a significant
reduction in the cost of patient care.
T9 ft
In a similar study Windsor and colleagues randomised 34 patients with acute
pancreatitis to receive either early enteral nutrition or parenteral nutrition. The route
of delivery of the enteral nutrition was dependent on the prognostic severity of the
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episode. In patients with prognostically mild disease enteral nutrition was taken
orally, whilst enteral nutrition was delivered through a radiologically positioned
nasojejunal tube in those with prognostically severe disease. The introduction of
early enteral nutrition was associated with a significant reduction in serum
C-reactive protein concentrations and APACHE II scores. Further, the use of
parenteral nutrition was associated with a reduction in serum anti-oxidant potential,
which is consistent with the presence of an on-going inflammatory response.
In contrast to the other two studies, all patients in the randomised controlled trial
reported by Kalfarentzos 327 had prognostically severe disease. In total 38 patients
were randomised to receive either enteral nutrition or parenteral nutrition. Again
enteral nutrition was delivered distal to the ligament of Trietz through a
radiologically screened feeding tube. Even in this population of patients with severe
disease enteral nutrition was well tolerated, with the protein and caloric intake
equalling that administered to the patients receiving parenteral nutrition. This ability
to provide adequate nutrition via the enteral route appeared to translate into a clinical
benefit. In those patients receiving enteral nutrition there were significantly fewer
complications and a significant reduction in the number of infectious episodes.
Further, the cost of nutritional support in the enteral feeding group was one third of
that in the parenteral nutrition group.
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Hypothesis
Current models of acute pancreatitis hold that remote organ dysfunction in acute
pancreatitis is a consequence of the development of a systemic inflammatory
response which is characterised by the interaction of activated leukocytes, activated
endothelial cells, and the secretion of inflammatory mediators such as cytokines.
Although a body of evidence exists supporting the presence of activated leukocytes
and increased pro-inflammatory cytokine secretion in severe acute pancreatitis, little
evidence exists regarding the role of the endothelial cell. This is due in part to the
inaccessibility of endothelial cells. However, the endothelial cell surface adhesion
molecules, E-selectin and P-selectin, may be readily assayed in serum following
endothelial cell surface expression thereby providing a measure of endothelial cell
function. Therefore in order to provide information regarding the role of the
endothelial cell in the pathogenesis of severe acute pancreatitis the kinetics of serum
soluble E-selectin and P-selectin have been determined in patients with mild and
severe acute pancreatitis. It is hypothesised that serum soluble E-selectin and
P-selectin concentrations will be increased in patients with severe acute pancreatitis
when compared to those with mild disease reflecting the increased endothelial cell
activation that occurs in those patients with severe disease.
Although it is now accepted that organ dysfunction in patients with severe acute
pancreatitis is mediated in part by increased pro-inflammatory cytokine secretion, the
mechanisms which result in differential secretion of pro-inflammatory cytokines
between individuals with mild or severe acute pancreatitis are not known. As in
other biological systems, cytokine secretion is determined by both environmental and
genetic factors. Although environmental factors may be important in mediating
increased cytokine secretion in severe acute pancreatitis none have been proven to be
the primary mechanism through which differential cytokine secretion occurs.
However, polymorphisms have been identified within cytokine gene loci which have
been demonstrated to have functional relevance to levels of cytokine secretion, and
moreover, have been demonstrated to have clinical significance in some
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inflammatory conditions. Such polymorphisms have been demonstrated in the
tumour necrosis factor and interleukin 1 family gene loci. Therefore the relationship
between polymorphisms within the tumour necrosis factor and interleukin 1 family
gene loci, and disease severity in acute pancreatitis have been determined. It is
hypothesised that gene polymorphisms which are associated with increased
pro-inflammatory cytokine activity will occur more frequently in patients with severe
acute pancreatitis. In addition, because the polymorphisms studied may not be the
most important polymorphisms with regard to determining cytokine secretion,
cytokine secretory phenotype has been determined following recovery from an
episode of acute pancreatitis. It is hypothesised that following a standard
inflammatory stimulus, increased leukocyte pro-inflammatory cytokine secretion
would be observed in those patients with previous severe acute pancreatitis when
compared to those with previous mild disease.
Finally, recent hypotheses have proposed that the maintenance of the systemic
inflammatory response in critical illness states is a consequence of intestinal
dysfunction which results in translocation of bacteria and bacterial products which
are potent inflammatory stimuli. Intestinal dysfunction in critical illness states is
believed to be due in part to the loss of nutrition following the implementation of a
nil-by-mouth regime. Further, it has been proposed that the introduction of enteral
nutrition is able to reverse intestinal dysfunction in critical illness states, thereby
ameliorating the inflammatory response. Therefore within the confines of a
randomised controlled trial, the effect of early enteral nutrition upon the
inflammatory response in patients with severe acute pancreatitis has been examined.
It is hypothesised that the introduction of early enteral nutrition will improve
intestinal barrier function, thereby reducing bacterial translocation resulting in a
reduction in the systemic inflammatory response.
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In summary the hypotheses tested within this thesis are:
1. That serum soluble E-selectin and P-selectin concentrations will be increased in
patients with severe acute pancreatitis when compared to those with mild disease
as a consequence of increased endothelial cell activation.
2. That cytokine gene polymorphisms associated with increased cytokine secretion
will have significant associations with disease severity in acute pancreatitis
3. That pre-determined differential leukocyte cytokine secretion exists between
individuals who have mild or severe acute pancreatitis.
4. That the introduction of early enteral nutrition in patients with prognostically
severe acute pancreatitis will improve intestinal barrier function, resulting in a




Kinetics Of Serum Soluble E-Selectin And P-Selectin In Acute
Pancreatitis
Patients
Eighteen patients admitted to the Royal Infirmary of Edinburgh with acute
pancreatitis were studied. Consistent with the Atlanta consensus conference
criteria , a diagnosis of acute pancreatitis was made on the basis of a history
consistent with acute pancreatitis and a serum amylase concentration greater than 3
times the upper limit of normal, or radiological (computed tomography) evidence of
acute pancreatitis. All patients within the present study had serum amylase
concentrations greater than 3 times the upper limit of normal, moreover all patients
with severe acute pancreatitis had evidence of acute pancreatitis on computed
tomographic scanning. Data were collected prospectively on all patients allowing
retrospective categorisation of disease severity according to criteria defined by the
Atlanta consensus conference 1. Because the present study aimed to determine levels
of endothelial dysfunction attributable to acute pancreatitis rather than other disease
processes, only patients with primary multiple organ dysfunction as defined by
current criteria set by the American College of Chest Physicians/Society of Critical
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Care Medicine were included in the group of patients with severe disease . The
patient characteristics are given in Table 9. The individual characteristics of those
patients with severe disease is given in Table 10. All patients with severe disease
had evidence of primary organ dysfunction; 5 (56%) patients required ventilation and
renal replacement therapy during the first three days of their admission. In total 6
patients (67%) with severe disease died of complications of acute pancreatitis during
their admission. The median time from admission to death was 38 days (range 2-135
days). In contrast no patient with mild acute pancreatitis had evidence of organ
dysfunction nor did any patient with mild disease succumb to their illness. As
current evidence indicates that the cytokine-mediated systemic inflammatory
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response syndrome responsible for organ dysfunction in acute pancreatitis occurs in
the initial stages of the disease and as the major focus ofpotential therapeutic
interventions is to modulate this early inflammatory response, the initial three days



























































































































Table10:Char cteristicsofpa ientw thsev rutp ncreatitisi homserlubleselec iconc nt atio sw determined. ERCP-endoscopicretrogradecholangiopancreaticogram.DIC-diss minatedintrav scul rcoagulation.MODS-mul plo dysfunctionsyndrome.
Sample Collection And Assay
After obtaining informed consent a venous blood sample was collected into a blood
tube without additive (Monovette® Sarstedt, Numbrecht Germany) and allowed to
clot. Samples were then centrifuged at 900g for 10 minutes. Serum was then
removed and stored at -70°C until analysis. Samples were collected on days 1, 2 and
3 of the in-patient stay. One patient in the severe group died on day 2. Because
haemoconcentration may affect serum soluble selectin concentrations, and the
Tin
platelet count may correlate with serum soluble P-selectin concentrations , venous
blood was also collected into ethylenediaminetetraacetic acid (EDTA) coated tubes
(Monovette® Sarstedt, Numbrecht Germany) for full blood count measurement.
Serum soluble E-selectin and P-selectin concentrations were measured by
enzyme-linked immunosorbent assay (R&D Systems, Abingdon UK). The lower
limit of detection for P-selectin and E-selectin measurement was 19ng/mL and
21ng/mL respectively. The P-selectin ELISA intra-assay and inter-assay coefficients
of variance were 2.4% and 4.6% respectively. The E-selectin ELISA intra-assay and
inter-assay coefficients of variance were 4.4% and 6.9% respectively.
Full blood count measurements were carried out using an automated cell counter
(Sysmey NE8000, Toa Medical Electronics, Japan).
Statistical Analysis
Patient characteristic variables are presented as median and interquartile range.
Serum soluble selectin and full blood count results are presented as mean and
standard error of the mean. Categorical data were compared using the %2 test.
Continuous data were compared using the Mann-Whitney U-test. Comparison of
repeated measurements between the two patient groups was carried out using
analysis of variance techniques (ANOVA). Significance was taken at the p=.05
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level. All analyses were carried out using the Statview 5.0 software package (SAS
Institute Inc, North Carolina).
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Cytokine Gene Polymorphisms In Acute Pancreatitis
Study Population
All patients admitted to the Royal Infirmary of Edinburgh with a diagnosis of acute
pancreatitis were eligible for study. The diagnosis of acute pancreatitis was based on
a history consistent with acute pancreatitis and serum amylase levels greater than
three times the upper limit of normal, or, radiological (computed tomography)
evidence of acute pancreatitis. Between September 1996 and May 1998 a total of
190 patients consented to enrolment in the study. Data on the clinical course were
collected prospectively allowing categorisation of disease severity according to
criteria defined by the Atlanta Consensus Conference '. Of the 190 patients enrolled,
113 had mild disease whilst the remaining 77 had severe disease. Further, in 169
patients who were admitted to the Royal Infirmary of Edinburgh at the onset of their
illness it was possible to quantify disease severity using the modified Glasgow
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prognostic scoring system . For the purposes of statistical analysis the aetiological
agent was categorised as being either gallstones, alcohol, idiopathic or "other". The
patient characteristics are shown in Table 11.
A control population consisting of 102 healthy individuals was derived from donors
attending the Lothian plasmapheresis centre. The control population consisted of 68
males and 34 females, with a median age of 42 years (IQR 36-47). In comparison to
patients presenting with acute pancreatitis the control group consisted of significantly
fewer females [97/190 (.51) vs 34/102 (.33), x2==8.42 p=.004] and was significantly
younger [53 (IQR 40-68) vs 42 (IQR 36-47), Mann-Whitney U p<.001)]. Although
there were fewer females in the control population, because the tumour necrosis
factor and interleukin 1 gene loci are on chromosome 6 and 2 respectively it is
unlikely that this difference would introduce bias into the study.
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Disease severity 1 Mild Severe
n=l 13 n=77
Age 51 (38-70) 57 (43-68) Mann-Whitney U p=. 156





Other 11 11 X2=3.42, p=.331
T91
Glasgow score 1 (0-2) n=l 11 4 (3-5) n=58 Mann-Whitney U p<.001
Table 11: Characteristics of patients with acute pancreatitis in whom
genotype analysis was carried out.
Values are median (interquartile range).
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Genotype Analysis
Following informed consent, a 2.5ml sample of peripheral venous blood was
collected directly into a blood tube containing ethylenediaminetetraacetic (EDTA)
(R)
acid (Monovette Sarstedt, Numbrecht Germany). Samples were stored at -70°C
until required at which point they were thawed to room temperature. Extraction and
purification of genomic DNA from venous blood was carried out using the Puregene
DNA isolation kit (Gentra systems, North Carolina, USA) according to the
manufacturer's instructions. The Puregene DNA isolation kit uses a salting out
i
technique . Purified genomic DNA was stored at -20°C.
The distributions of the following four cytokine gene polymorphisms were
determined:
TNF-308. A single base G to A substitution may occur at position -308 in the TNFa
promoter. This substitution may be identified using polymerase chain reaction gene
amplification with subsequent endonuclease digestion 212. A 107 base pair fragment
of the TNFa promoter region from position -331 to -226 was amplified using the
primers shown in Table 12. The PCR reaction mixture is given in Table 13. The
thermal cycler protocol is given in Table 14. Following gene amplification, PCR
products were digested using the Ncol endonuclease. The reaction mixture and
duration of digestion is shown in Table 15. Digestion products were separated on
9% polyacrylamide gels at a constant voltage of 200V, with subsequent visualisation
using ethidium bromide. The cleaved product bands of 87 and 20 base pair lengths
represent allele 1 while the uncleaved 107 base pair product represents allele 2
(Figure 3). A permanent record was made using Polapan 665 or 667 Polaroid film.
TNFB. A bi-allelic Ncol restriction fragment length polymorphism exists in intron 1
of the tumour necrosis factor p gene. This polymorphism may be identified using
polymerase chain reaction gene amplification with subsequent endonuclease
digestion. A 368 base pair fragment of the TNFB gene locus was amplified using the
primers shown in Table 12. The PCR reaction mixture is given in Table 13. The
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thermal cycler protocol is given in Table 14. Following gene amplification, PCR
products were digested using the Ncol endonuclease. The reaction mixture and
duration of digestion is shown in Table 15. Digestion products were separated on
1% agarose gels at a constant voltage of 200V, with subsequent visualisation using
ethidium bromide. The cleaved product bands of 586 and 196 base pair lengths
represent allele 1 while the uncleaved 782 base pair product represents allele 2
(Figure 4A). A permanent record was made using Polapan 665 or 667 Polaroid film.
Because the primers for the TNFB gene produced other PCR products which could
be clearly defined using 6% polyacrylamide gels (Figure 4B), further confirmation
that the digestion products were derived from the TNFB gene was required. To
demonstrate that the digestion products were derived from the desired TNFB gene
locus Southern blot analysis was carried out. A digoxigenin labelled DNA probe
(5'-CAGGCAGCAGAACCAGCAGCAGT-3') was constructed. Electrophoretic
separation was carried out on 1% agarose gels, which were then neutralised in 0.25M
NaCL/0.5M Tris HC1 pH7.5 for 1 hour followed by 20xSSC (saline sodium citrate)
for 10 minutes. DNA blotting to a nylon membrane was carried out overnight using
capillary transfer with 20xSSC. The nylon membrane was exposed to ultraviolet
light for 5 minutes in order to achieve fixation ofDNA to the membrane.
Non-specific DNA probe blocking was minimised by pre-hybridising the membrane
in 5xSSC/5xDenhardt's solution/100pg/mL salmon testes DNA for a period of 4
hours. DNA probe hybridisation was carried out using 3.7 nmol/L of labelled probe
in 5xSSC/lxDenhardf s solution/100pg/mL salmon testes DNA for 16 hours at a
temperature of 60.5°C. The nylon membranes were then buffered in a series of
solutions each for a period of 20 minutes (solution 1 - 0.1%SDS/2xSSC : solution 2 -
0.1%SDS/0.2xSSC : solution 3 - 0.1%SDS/0.16xSSC). Detection of the digoxigenin
labelled probe was carried out using an alkaline phosphatase conjugated
anti-digoxigenin Fab fragment and the chemoluminescent compound CSPD
(disodium 3-(4methoxyspirofl,2-dioxetane-3,2'-(5'-chloro) tricyclo
3 7
[3.3.1.1 ' ]decan-4yl0 phenyl phosphate). Probe detection was carried out using a
DIG Luminescent Detection Kit from Roche Diagnostics according to the
manufacturers instructions. Southern blot confirmed that the PCR bands visualised
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following endonuclease digestion of the PCR products were indeed amplified from
the TNFB gene (Figure 5). Southern blotting was not carried out for every individual
within the study once it was demonstrated that the TNFB digestion products could be
consistently and accurately identified.
ILip. A biallelic Taql restriction fragment length polymorphism exists in exon 5 of
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the ILip gene . This polymorphism may be identified using polymerase chain
reaction gene amplification with subsequent Taql endonuclease digestion. A 678
base pair fragment of the IL1B gene locus from position +4180 to +4858 was
amplified using the primers shown in Table 12. The PCR reaction mixture is given
in Table 13. The thermal cycler protocol is given in Table 14. Following gene
amplification, PCR products were digested using the Taql endonuclease. The
reaction mixture and duration of digestion is shown in Table 15. Digestion products
were separated on 6% polyacrylamide gels at a constant voltage of 200V, with
subsequent visualisation using ethidium bromide. The cleaved product bands of 156
and 522 base pair lengths represent allele 1 while the uncleaved 678 base pair
product represents allele 2 (Figure 6). A permanent record was made using Polapan
665 or 667 Polaroid film.
IL1RN. An 86 base pair variable number tandem repeat sequence exists in intron 2
of the interleukin 1 receptor antagonist gene (IL1RN) 249. Previous studies have
identified the potential for 5 different alleles. This polymorphism may be identified
using polymerase chain reaction gene amplification of the IL1RN gene locus
between +1990 and +2156 which spans the tandem repeat sequence. The DNA
primers used are shown in Table 12. The PCR reaction mixture is given in Table 13.
The thermal cycler protocol is given in Table 14. PCR products were separated on
6% polyacrylamide gels at a constant voltage of 200V, with subsequent visualisation
using ethidium bromide. PCR product bands of various lengths were identified and
correspond to the following alleles; 412 base pair (allele 1), 240 base pair (allele 2),
326 base pair (allele 3), 426 base pair (allele 4), 584 (allele 5) (Figure 7). A
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Figure 3: TNF -308 Gene Polymorphism.
A) PCR with primers designed to include position -308 of the TNFa gene. PCR product of
107 base pair length. Electrophoresis on 9% polyacrylamide gel.
B) Nco1 endonuclease digestion of TNF-308 PCR product demonstrating digestion
fragments of 107 and 87 base pair length. Digestion product of 20 base pair length is
too small to be displayed on the gel. Lanes 1, 2, 3, 4, 6, 8 and 11 homozygous allele 1;
lanes 5, 10 and 13 heterozygous allele 1 and 2; lanes 7, 9 and 12 homozygous allele 2.
Electrophoresis on 9% polyacrylamide gel.
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Figure 4: TNFB gene polymorphism.
PCR with TNFB primers followed by Nco1 endonuclease digestion. Product band lengths
correspond to the following alleles: allele 1 - 586 and 196 base pair; allele 2- 782 base pair.
A) PCR with TNFB primers followed by Nco1 endonuclease digestion. Electrophoresis on
1% agarose gel. Lane 1 homozygous allele 2; lane 2 heterozygous allele 1 and 2; lane
3 homozygous allele 2; lane 4 homozygous allele 1.
B) PCR with TNFB primers followed by Nco1 endonuclease digestion. Electrophoresis on
6% polyacrylamide gel. Lanes 1, 5, 7, 10 and 12 homozygous allele 2; lanes 4, 6, 8, 9
and 11 heterozygous allele 1 and 2; lanes 2 and 3 homozygous allele 1. Note additional
bands clearly visible on polyacrylamide gel but not on agarose gel.
77
Figure 5: Southern blot for TNFB gene.
A) TNFB genotype on 1% agarose gel. Lane 1 homozygous allele 2; lane 2 heterozygous
allele 1 and 2; lane 3 homozygous allele 1.
B) Southern blot using labelled probe directed at TNFB genotype PCR product. Lane 1
homozygous allele 2; lane 2 heterozygous allele 1 and 2; lane 3 homozygous allele 1.
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Figure 6: ILip gene polymorphism.
PCR with IL1B primers followed by Taq1 endonuclease digestion. Electrophoresis
on 6% polyacrylamide gel. Product band lengths correspond to the following alleles:
allele 1-156 and 522 base pair; allele 2- 678 base pair. Lane 1 homozygous allele
2; lanes 3, 8 and 13 heterozygous allele 1 and 2; lanes 2, 4, 5, 6, 7, 9, 10, 11 and 12
homozygous allele 1.
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Figure 7: IL1RN gene polymorphism.
PCR with IL1RN primers to detect the variable number tandem repeat sequence
within the IL1RA gene. PCR product length corresponds to the following alleles:
412 base pair (allele 1), 240 base pair (allele 2), 326 base pair (allele 3), 426 base
pair (allele 4), 584 base pair (allele 5). Electrophoresis on 6% polyacrylamide gel.
A) PCR with IL1RN primers. Lane 1 homozygous allele 1; lane 2 heterozygous
allele 1 and 2; lane 3 heterozygous allele 1 and 4; lane 4 homozygous allele 2;
lane 5 heterozygous allele 2 and 3.
B) PCR with IL1RN primers. Lanes 1, 3, 5 and 6 homozygous allele 1; lane 2




Comparison of allelic and genotypic frequencies was carried out using the % test.
Continuous variables are presented as median and interquartile range. Continuous
variables were compared using the non-parametric Mann-Whitney U, Wilcoxon
signed rank and Kruskal-Wallis tests thereby avoiding any distributional
assumptions. Statistical significance was taken at the p=.05 level. The relationship
between the carriage of individual alleles and disease severity is presented as odds
ratio with 95% confidence interval (OR 95%C.I.). Statistical analysis was carried
out using the Statview 5.0 software package (SAS Institute, North Carolina, USA).
Ethical Approval
This study was approved by the Lothian ethics committee. Informed consent was
obtained from all participants or from the next of kin if the participant was unable to
give consent.
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Cytokine Phenotype In Acute Pancreatitis
Study Population
Because down-regulation of leukocyte function may occur during the systemic
inflammatory response syndrome , patterns of cytokine secretion were determined
following recovery from the episode of acute pancreatitis. Surviving patients who
had previously consented to the genotype studies were invited by letter to the
out-patient clinic with the intention of studying patterns of cytokine secretion.
Patients were deemed to have recovered from their acute pancreatitis if they had no
on-going symptoms related to their acute pancreatitis, nor an on-going complication.
Patients were excluded from study if they were taking either non-steroidal
anti-inflammatory drugs (NSAIDs) or immunosuppressive therapy. In total 57
patients responded to the request, however 6 patients were ineligible for study
because they were currently taking NSAIDs or corticosteroids. A total of 51 patients
were therefore eligible for phenotype analysis. The characteristics of this subgroup
are shown in Table 16. There were no significant differences with respect to age
(Mann-Whitney U p=.276), sex (x2=0.10, p=.752), aetiology (x2=5.12, p=.160),
Glasgow score (Mann-Whitney U p=. 119) and end of episode disease severity
(X =2.09, p=.149) between those individuals who did or did not undergo
post-episode cytokine analysis (Table 17). The median interval between discharge
from hospital discharge to determination of cytokine phenotype was 287 days (IQR
189.5-465.5). Further, in order to quantify any inflammatory response still present,
serum C-reactive protein concentrations were assayed. For the 51 patients studied
the median C-reactive protein concentration was <1.0g/dL (IQR <1.0-1. 9 g/dL).
As would be expected those with severe acute pancreatitis had significantly higher
Glasgow scores than those with previous mild disease (Mann-Whitney U p<.001).
Interestingly, there was a significant difference in the aetiological agent inducing
acute pancreatitis between the two groups (x2=8.31, p=.040). Although the majority
of cases of severe acute pancreatitis were due gallstones and alcohol excess, in 6
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individuals the aetiological agents were post-endoscopic retrograde
cholangio-pancreatography (2), hyperlipidaemia (1), angiography (1), diabetic
ketoacidosis (1) and pancreas divisum (1). All cases ofmild acute pancreatitis were




Age 58(45-73) 55 (41-63) Mann-Whitney U p=.337





Other 0 6 X2=8.31,p=.040
"39 1
Glasgow score 2(1-3) n=25 4(3-5) n=18 Mann-Whitney U p<.001
Table 16: Characteristics of patients undergoing phenotype analysis.
Patient characteristics for those patients undergoing phenotype analysis




Age 57 (44-70) 51 (39-69) Mann-Whitney U p=.276





Other 6 16 X2=5.12, p=. 160
Severity 1 26 mild:25 severe 87 mild:52 severe X2=2.09, p=.149
111
Glasgow score 3 (1-4) n=43 2 (1-4) n=126 Mann-Whitney U p=.l 19
Table 17: Characteristics of participants and non-participants of
phenotype studies.
Comparison of characteristics of patients who underwent determination of
cytokine secretory patterns with those of patients not participating. Stated
values are median (interquartile range).
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Cytokine Secretion Studies
Cytokine production was determined using an ex-vivo whole blood culture
technique . The whole blood technique has previously been demonstrated to be
reproducible and accurate in the investigation of genetically determined cytokine
levels 334. In brief 5mL of peripheral venous blood was collected into heparinised
blood tubes (Monovette® Sarstedt, Germany). A total of 2mL heparinised venous
blood was diluted 1 in 10 with RPMI culture medium (Life Technologies, Paisley
UK) supplemented with penicillin 50units/mL, streptomycin 50pg/mL and glutamine
2mmol/L. Aliquots of 2mL were cultured in 16 well culture plates (Corning Costar,
High Wycombe UK) at 37°C, humidified with 5% CO2. Paired samples were
stimulated with lipopolysaccharide (LPS) derived from Escherichia coli 0127:B8
(Sigma, Poole UK). LPS was chosen as the experimental stimulus because previous
studies have suggested that endotoxin has a major role in promoting the
inflammatory response in human acute pancreatitis 92'96'318'319. Following
incubation samples were removed from the culture plate and centrifuged at 450G for
5 minutes. The supernatants were stored at -70°C until measurement of cytokine
concentration.
Culture supernatant cytokine concentrations were determined by commercially
available enzyme-linked immunosorbent assay (ELISA) kits: TNFa (CLB,
Amsterdam The Netherlands), ILip (R&D Systems Europe, Abingdon UK) and
IL1RA (R&D Systems Europe, Abingdon UK). Culture supernatant cytokine
concentrations were determined for paired samples. The lower limits of detection
were as follows: TNFa 14pg/mL, ILip 20 pg/mL, IL1RA 285pg/mL. The
intra-assay and inter-assay coefficients of variation for each assay were: TNFa
14.9% and 8.9%, ILip 4.2% and 8.3%, IL1RA 3.8% and 15.6%.
Peripheral venous blood was also collected at the same time as blood for whole
blood culture for the determination of haematological indices. A total of 2.5mL
venous blood was collected into tubes containing EDTA. Haemoglobin
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concentration and white blood count and differential were carried out on an
automated analyser (Sysmey NE8000, Toa Medical Electronics, Japan).
Experimental Conditions For Determining Cytokine Phenotype
In order to determine the optimum concentration of LPS and duration of incubation
for determining patterns of cytokine secretion, a series of trial experiments was
carried out.
In the first experiment venous blood was obtained from 7 unrelated healthy
individuals. Whole blood cultures were stimulated with increasing concentrations of
lipopolysaccharide; Opg/mL, 5pg/mL and 10 pg/mL. Cultures were then incubated
for either 8 or 24 hours. The TNFa supernatant concentrations are shown in
Figure 8. After 8 hours incubation, when compared to the unstimulated sample
TNFa concentration was significantly higher following stimulation with 5pg/mL
LPS (p=.028, Wilcoxon signed rank) and lOpg/mL LPS (p=.028, Wilcoxon signed
rank), however there was no significant difference in TNFa secretion between the
samples stimulated with 5pg/mL LPS or lOpg/mL LPS (p=.249, Wilcoxon signed
rank). Similarly following 24 hours incubation, when compared to the unstimulated
sample, TNFa concentration was significantly higher following stimulation with
5pg/mL LPS (p=.018, Wilcoxon signed rank) and lOpg/mL LPS (p=.018, Wilcoxon
signed rank). Again there was no significant difference in TNFa secretion between
the samples stimulated with 5pg/mL LPS or lOpg/mL LPS (p=.398, Wilcoxon
signed rank). Interestingly, supernatant TNFa concentrations were significantly
higher after 8 hours than 24 hours incubation following stimulation with either
5pg/mL LPS (p=.028, Wilcoxon signed rank) or lOpg/mL LPS (p=.028, Wilcoxon
signed rank).
In order to further define an optimum duration of culture, paired samples derived
from 7 unrelated healthy individuals were stimulated with LPS at a final
concentration of 5pg/mL or were left unstimulated. Samples were incubated for a
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period of 1, 4 or 8 hours. The results are shown in Figure 9. At all time points the
concentration ofTNFa was significantly higher in the stimulated sample when
compared to the unstimulated sample (1 hour p=.0180 Wilcoxon signed rank, 4 hours
p=.0180 Wilcoxon signed rank and 8 hours p=.0277 Wilcoxon signed rank). Further,
there was a significant increase in TNFa concentrations in the stimulated samples
over the study period (ANOVA p<.001). Similarly, although the rise over time was
small, TNFa concentrations increased significantly in the unstimulated samples over
the study period indicating spontaneous secretion of TNFa (ANOVA p=.007).
Following these experiments a decision was made that for the cytokine secretory
phenotype studies paired samples were to be cultured with or without LPS at a final
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Figure 8: Whole blood TNFa secretion following lipopolysaccharide
stimulation at differing concentrations.
Box plot of whole blood supernatant TNFa concentrations following stimulation with
lipopolysaccharide; Opg/mL, 5pg/mL and 10 ng/mL. Whole blood cultures were incubated
for either 8 or 24 hours. Venous blood was obtained from 7 unrelated healthy individuals.
Box plot illustrates median and 10f,th 25th ,75th and 90th centiles.
8 hours incubation
LPS Opg/rnL vs LPS 5ng/mL
LPS Opg/mL vs LPS 10ng/mL
LPS 5pg/mL vs LPS 10pg/mL
24 hours incubation
LPS Opg/rnL vs LPS 5pg/mL
LPS 0|ag/mL vs LPS 10pg/mL
LPS 5ng/mL vs LPS 10pg/mL
p=.028, Wilcoxon signed rank
p=.028, Wilcoxon signed rank
p=.249, Wilcoxon signed rank
p=.018, Wilcoxon signed rank
p=.018, Wilcoxon signed rank
p=.398, Wilcoxon signed rank
LPS 5/ug/mL
8 hours vs 24 hours p=.028, Wilcoxon signed rank
LPS 10jug/mL















1 hour 4 hours 8 hours
Figure 9: Whole blood TNFa secretion following lipopolysaccharide
stimulation at differing time points.
Box plot of whole blood supernatant TNFa production over an 8 hour period. Venous blood
was obtained from 7 unrelated healthy individuals. Paired samples were incubated with
stimulation using LPS at a final concentration of 5pg/mL or without stimulation. Whole blood
cultures were incubated for 1, 4 or 8 hours. At all time points TNFa concentration was
significantly higher in the stimulated samples when compared to the unstimulated sample (1
hour p=.0180, Wilcoxon signed rank, 4 hours p=.0180, Wilcoxon signed rank and 8 hours
p=.0277, Wilcoxon signed rank). In both stimulated and unstimulated samples the
concentration of TNFa increased over the study period (unstimulated ANOVA p=.007,
stimulated p<.001). Box plot illustrates median and 10th, 25th ,75th and 90th centiles.
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Statistical Analysis
Continuous variables are presented as median and interquartile range. Continuous
variables were compared using the non-parametric Mann-Whitney U, Wilcoxon
signed rank and Kruskal-Wallis tests thereby avoiding any distributional
assumptions. However, for the experiments using repeated measures over time an
analysis of variance (ANOVA) technique was also used. Statistical significance was
taken at the p=.05 level. Statistical analysis was carried out using the Statview 5.0
software package (SAS Institute, North Carolina, USA).
Ethical Approval
This study was approved by the Lothian regional ethics committee. Informed
consent was obtained from all participants.
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Enteral Nutrition In Prognostically Severe Acute Pancreatitis
Patients
Patients admitted with prognostically severe acute pancreatitis within 72 hours of the
onset of symptoms were eligible for study. The diagnosis of acute pancreatitis was
based on a history consistent with acute pancreatitis and a serum amylase
concentration greater than three times the upper limit of normal or radiological signs
of acute pancreatitis at computed tomography. Prognostication of disease severity
• -291 T9Q •
was carried out using the Glasgow and APACHE II scoring systems. Patients
were considered to have prognostically severe acute pancreatitis if they had a
Glasgow score > 3 and, or, an APACHE II score > 7. Patients were excluded from
study if their age was less than 18 or greater than 80, if they were pregnant, if they
had previously received nutritional support or if they were enrolled in another
clinical trial.
During the period 16th December 1996 to 1st July 1998, 156 patients were admitted to
the Royal Infirmary of Edinburgh with a diagnosis of acute pancreatitis. Of those
patients 51 were eligible for inclusion in the study, however 17 refused entry, 3
patients were entered into another trial, 1 patient was commenced on normal diet
within 24 hours of admission, in 1 patient the diagnosis was initially missed and 1
patient succumbed to their disease before they could be entered into the trial. A total
of 28 patients met the entry criteria and were randomised. One patient who met all
of the entry criteria was subsequently found at laparotomy to have an acute
mesenteric infarction and was therefore withdrawn from the trial. The results of this
individual have been excluded from analysis.
Following informed written consent patients were randomised in blocks of variable
even numbers to receive either conventional therapy plus early enteral nutrition or
conventional therapy alone. Randomisation in blocks was employed to reduce the
potential for clustering in one or other arm within in a small study population. The
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individual responsible for drawing the randomisation card was unaware of the
number of patients in each randomisation block. Patients with an APACHE II score
of >20 were stratified and randomised separately to minimise the potential for
clustering of patients with very severe disease in one treatment arm.
To further define the severity of the acute pancreatitis at admission to the study, a
contrast-enhanced computed tomography was carried out on each patient as soon as
• ^99
was practicable allowing calculation of the Balthazar and Helsinki prognostic
scores, both of which have been validated in the determination of severe disease.
For the purpose of statistical analysis, the aetiological agent was categorised as either
gallstone, alcohol, idiopathic or other.
The demographics of the study sample are shown in Table 18.
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Table18:Demographicsfpatientsr ndomis die teralnutr tiontri l. Statedvaluesrmedian(rang ).
Study Endpoints
The primary endpoint of this study was modulation of markers of the inflammatory
response in patients with predicted severe acute pancreatitis. As measures of the
systemic inflammatory response the following were assayed: serum C-reactive
protein (CRP), serum interleukin 6 (IL6) and serum soluble TNF receptor I
(sTNFR-I). Levels of serum IL6 and sTNFR-I have previously been demonstrated to
increase early in patients with acute pancreatitis and to correlate with disease
severity 91. Serum CRP concentrations have also been demonstrated to correlate
with disease severity but peak levels occur 24-48 hours after the peak for IL6
concentrations 143. As an indirect measure of exposure to endotoxin, serum
anti-endotoxin core IgG antibody concentrations were assayed. Previous evidence
indicates that endotoxin may be a potent stimulus for the systemic inflammatory
response in severe acute pancreatitis and that endotoxin exposure can be a
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consequence of intestinal dysfunction ' ' . Levels of serum IgG anti-endotoxin
core antibody have been demonstrated to reflect previous endotoxin exposure and
can aid in the identification of patients with acute pancreatitis at risk of developing
organ dysfunction 31 .
The secondary endpoints were the safety and tolerance of early enteral nutrition,
markers of intestinal dysfunction and organ dysfunction scores,
i. Safety And Tolerance OfEarly Enteral Nutrition: For each 24 hour period the
volume of feed delivered was measured. All adverse events that were
potentially attributable to enteral nutrition were recorded. A simple graded
nausea score (0= no nausea, 1= nausea present, 2= vomiting) was used and
patients were assessed daily to quantify nausea. In order to assess the potential
of early enteral nutrition to modify the catabolic processes found in severe acute
pancreatitis, urinary nitrogen excretion was calculated for each 24 hour period,
ii. Modulation OfIntestinal Dysfunction: Intestinal permeability was determined
• • 9 f\f\ lf\l
using a differential sugar permeability test ' . The urinary excretion of the
orally administered non-absorbable probes L-rhamnose (monosaccharide) and
lactulose (disaccharide) was measured to determine intestinal permeability.
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iii. Organ Dysfunction: Organ dysfunction was quantified using the Marshall
organ dysfunction scoring system 336. The Marshall organ dysfunction score
summates individual scores for cardiovascular, respiratory, renal,
haematological, neurological and hepatic function giving rise to a score
between 0 and 24 inclusive.
Study Period
The patient was deemed to have completed the study following the introduction of
normal diet, the wish to be removed from the trial or upon completion of the tenth
day.
Conventional Therapy
Conventional therapy was in accordance with current British Society of
Gastroenterology guidelines for the management of patients with acute
pancreatitis l4. This consisted of a nil-by-mouth regime, fluid resuscitation, oxygen
therapy as required, urethral catheterisation with hourly monitoring of urine volume
and opiate analgesia. Central venous cannulation was carried out at the discretion of
the treating physician. Metabolic abnormalities were corrected when present. Organ
support was carried out as required. In light of recent randomised controlled trials
demonstrating the benefit of prophylactic antibiotic therapy in patients with severe
acute pancreatitis , all patients were prescribed intravenous cefotaxime 2g and
metronidazole 500mg three times daily for 4 days. In patients with a history of
hypersensitivity to cephalosporins or penicillins, ciprofloxacin was prescribed in
place of cefotaxime. After 4 days all antibiotic therapy was stopped, with further
antibiotic therapy being prescribed according to antibiotic sensitivities of positive
bacteriological cultures, or empirically at the discretion of the treating clinician.
All patients had contrast-enhanced computed tomography. Radiological severity of
acute pancreatitis was quantified using the Balthazar 322 and Helsinki 335 scoring
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systems. In addition patients without evidence of gallstones on CT underwent
trans-abdominal ultrasonography to determine the presence or absence of gallstones.
In line with current evidence, early ERCP was only carried out in patients with




Single lumen 110 cm 8 French (Corsafe® Merck, Middlesex UK) nasojejunal feeding
tubes were placed under flouroscopic screening such that the tip of the nasojejunal
feeding tube was distal to the ligament of Treitz. The duration of radiological
screening taken to achieve the correct tube position was recorded. Tube
dislodgement episodes were defined as a loss of tube position such that the tip of the
nasojejunal feeding tube was no longer distal to the ligament of Trietz. Routine
radiological assessment of the position of the tip of the feeding tube following the
initial radiological screening procedure was not carried out. Enteral nutrition was
commenced at a rate of 25mL/hr, increasing daily by 25mL/hr until the desired
caloric intake, as determined by the Schofield equation 339, was reached. Nasojejunal
tubes were initially aspirated 4 hourly to exclude pooling of feed. In the presence of
signs of feed intolerance (increasing abdominal distension, regurgitation, high
nasojejunal tube aspirates) the infusion rate was not increased.
Although studies exist suggesting maximal benefit from the use of an
immune-enhancing nutrition supplement 290'29\ these data had not been reported at
the time of the inception of the present study, and therefore a standard nutritional
formulation was used. Jevity® (Abbott, Berkshire UK), a polymeric formula
containing fibre, was used in all cases. 500 ml Jevity contains 4g protein, 3.5g fat,
13.1 g carbohydrate and 1.4g dietary fibre providing 2105 kilojoules.
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Laboratory Tests
Venous blood sampling was carried out at 0800 each day. Blood samples were
centrifuged at 900G for 10 minutes. Serum was then removed and stored at -70°C
until analysis.
Serum CRP was assayed at admission and on days 2,4,7 and 10 using an automated
fluorometric immunoassay technique (Abbott, Berkshire UK). The lower limit of
detection was O.lmg/dL. The inter-assay coefficient of variation was less than 10%.
Serum IL6 was measured on admission and on days 2 and 4 using an enzyme-linked
immunoassay technique (ELISA) (CLB, Amsterdam The Netherlands ). The lower
limit of detection was 33pg/mL. The intra-assay and inter-assay coefficients of
variation were 1.6% and 4.0% respectively.
Serum sTNFR-I was measured at admission and on days 2,4,7 and 10 using an
ELISA technique (R&D Systems, Abingdon UK). The lower limit of detection was
156pg/mL. The intra-assay and inter-assay coefficients of variation were 7.1% and
7.6% respectively.
Total urinary nitrogen excretion was calculated through the measurement of urinary
urea. Urinary urea concentration was determined using an automated analyser and
was carried out by Quintiles (Edinburgh UK). From this the total urinary nitrogen
excretion was calculated, following the assumption that urinary urea nitrogen
accounts for only 80% of urine nitrogen loss.
Serum anti-endotoxin core antibody concentration were assayed using an ELISA
technique (Coaset Endocab Chromogenix, Molndal Sweden). The lower limit of
detection was 6MU/mL. The intra-assay and inter-assay coefficients of variation
were 14.2% and 9.7% respectively.
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Urinary excretion of non-absorbable sugars was measured on admission and on days
4 and 10. Following a period of fasting of no less than 8 hours, a solution containing
lactulose 5g, L-rhamnose lg, sucrose 20g and lactose 20g (Ninewells
Pharmaceuticals, Dundee UK) dissolved in 80 ml water was administered orally.
Lactose and sucrose were used to increase the osmolality of the sugar solution,
thereby increasing the sensitivity of the test. Following administration urine was
collected for the next 5 hours. Urine sugar concentration was determined by high
performance liquid chromatography within the Department ofGastroenterology,
Western General Hospital, Edinburgh. Urinary lactulose/rhamnose (L/R) ratio was
calculated and compared to a previously determined normal laboratory reference
range. Increased L/R ratio is indicative of small intestine injury, whilst the
absorption of sucrose indicates gastric injury. The disaccharide peak for lactulose
could not be quantified if other disaccharides were present. Further, excessive
glycosuria prevented L-rhamnose measurement. Intestinal permeability
measurements were categorised as "normal", "increased lactose/rhamnose ratio" and
"sucrose permeability". Samples with glucose present were excluded from statistical
analysis.
Sample Size Calculations
A previous study in which 34 patients with acute pancreatitis were randomised to
receive either early enteral or parenteral nutrition reported a 64% reduction in the
systemic inflammatory response syndrome in patients with acute pancreatitis
receiving early enteral nutrition 326. This study also reported a 54% reduction in CRP
in this group. There was a 77% difference in the cumulative incidence of sepsis,
multiple organ dysfunction, need for operative intervention and mortality between
patients receiving early enteral nutrition and those in the control arm. On this basis a
50% reduction in the markers of the inflammatory response used in this study would
be detected with 80% power, (a=0.05) with 12 patients in each arm.
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Statistical Analysis
In the majority of instances stated values are median (range) with statistical analysis
being carried out using non-parametric tests to avoid distributional assumptions.
However, for the comparison of repeated measurements over the study period mean
(standard error) are given and analysis of variance techniques (ANOVA) were used.
In all cases a two tailed test was used. Statistical significance was taken at the p=.05
level. Statistical analysis was carried out using the Statview 5.0 software package
(SAS Institute, North Carolina, USA).
Ethical Approval
This study was approved by the Lothian research ethics committee. Informed
consent was obtained from the patient or their next of kin.
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Results
Kinetics Of Serum Soluble E-Selectin And P-Selectin In Acute
Pancreatitis
Serum Selectin Levels
The pattern of serum soluble E-selectin over the first 3 days of admission to hospital
in patients with acute pancreatitis is demonstrated in Figure 10A. There was no
significant association between serum soluble E-selectin concentration and the day of
sample (ANOVA p=.090). Similarly, no significant association existed between
serum soluble E-selectin concentration and disease severity (ANOVA p=.451).
However, with respect to serum soluble E-selectin concentration a significant
interaction existed between the day of sample and disease severity (ANOVA
p=.044). The pattern of increasing serum soluble E-selectin concentrations over the
first 3 days in patients with severe disease is significantly different from the pattern
observed in patients with mild disease. Similarly serum soluble E-selectin
concentrations increased over the first three days of admission in non-survivors, and
were significantly different from the pattern observed in survivors (Figure 10B.
ANOVA P=.001).
The pattern of serum soluble P-selectin over the first 3 days of admission to hospital
in patients with acute pancreatitis is demonstrated in Figure 11A. In patients with
mild and severe acute pancreatitis a significant fall in serum soluble P-selectin
concentrations was observed (ANOVA p<.001). There was no significant difference
in serum soluble P-selectin concentrations between patient groups (ANOVA p=.366).
There was also no significant interaction between the day of sample and disease
severity in determining serum soluble P-selectin concentrations (ANOVA p=.254).
In contrast, with respect to mortality, serum soluble P-selectin concentrations were
significantly higher over the first three days of admission in non-survivors than in
survivors (Figure 1 IB. ANOVA P=.005), primarily on day 1.
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Figure10:Ser msol blE-selectinconcentratio sipati n sw hacutepa r ati iovthfirshr ed ysf admission. A)Serumsol bleE- electinconcentratio sipati n sw hm ld(n=9)as v redise se.Thobs rv dpat rfincr asingrumolub E-selectinconc ntrat onipati n sw ths vereacutpancr a itisassig ific ntlydifferfromthoswi hmi ds se(ANOVAp=.044). B)Serumsol bleE- electinconcentrationswi hr specttm rtality.Thobservedinc ass rumolubE- el ctincon e tratio sn - urvivors (n=6)wassignificantlydifferentfromsurvivor(n=12)ANOVAp=.001). Valuesrmeanwither orb sindicatingstand rdrroofthme n(SEM).
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Figure11:Ser msol bleP-selectinconcentratio sipati n sw ha tea reati iovthfirshr ed ysf admission. A)Serumsol bleP-selectinconcentratio sipatientsw hm ld(n=9)as v redi se.Ovththrysch ng inserumconcentrationswasignifica t(ANOVAp<.001)bunoet enpatientgr ups. B)Serumsol bleP-selectinconcentratio swi hrespecttmo tali y.Ov rhfi rdaysfdmis i ,s rumoluble P-selectinconcentratio sw eignificantlyhigherinon-survivors(n=6)thasurvivors(n=12ANOVAp=.005).Val s meanwitherrorba sindicatingSEM.
Haematocrit And Platelet Counts
In patients with mild or severe pancreatitis there was a significant fall (ANOVA
p<.001) in haematocrit over the three day study period (Figure 12A). The fall in
haematocrit in patients with severe disease was significantly greater than the fall
observed in patients with mild disease (ANOVA p=.032). There was a significant
fall in platelet count in patients with mild and severe disease over the three day study
period (Figure 12B. ANOVA p<.001). Patients with severe acute pancreatitis had
lower platelet counts (ANOVA p=.031) than those with mild disease.
Stepwise backward logistic multiple factor regression analysis revealed no
association between platelet count and serum soluble P-selectin levels (haematocrit
F=21.89, white cell count F=0.82, platelet count F=3.34, intercept F=5.07; p<.001).
There was a significant negative correlation between the platelet count and serum
soluble E-selectin levels (haematocrit F=0.12, white cell count F=0.13, platelet count
F=7.98, intercept F=50.21; p=.007).
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Cytokine Gene Polymorphisms In Acute Pancreatitis
The frequency distribution of genotypes for the tumour necrosis factor gene
polymorphisms studied is shown in Table 19. There was no significant difference in
the distribution of tumour necrosis factor gene polymorphisms between patients with
mild or severe disease. Similarly, no significant difference in the rate of carriage of
the high secreting alleles was seen between the two patient populations. For the
TNF-308 polymorphism, allele 2 occurred in 42/113 (0.37) of patients with mild
i • • 2disease compared with 26/77 (0.34) patients with severe disease (x =0.23, p=.631;
OR 95%C.I. 0.47-1.58). Likewise TNFB allele 2 was found in 97/113 (0.86) patients
with mild disease compared with 68/77 (0.88) with severe disease (x =0.25, p=.621;
OR 95%C.I. 0.53-2.95). Further, there were no significant differences in the
TNF-308 or TNFB genotype frequency distributions between patients with acute
pancreatitis and healthy controls. For all subjects studied, individuals who were
homozygous for TNFB allele 2 were always homozygous for TNF-308 allele 1
(X2=l 19.00, p<.001).
The frequency distribution of genotypes for the IL1 (3 gene polymorphism is shown in
Table 20. There were no significant differences in genotype frequency distribution
between patients with mild or severe acute pancreatitis. Similarly, there was no
significant difference in the rate of carriage of the allele linked with high secretion of
ILip. Allele 2 was found in 43/113 (.38) of patients with mild disease compared
with 29/77 (.38) of patients with severe acute pancreatitis (x2=0.003, p=.957; OR
95%C.I. 0.54-1.78). No significant difference in genotype frequencies was observed
between the patients with acute pancreatitis and healthy controls.
The frequency distribution of genotypes for the IL1RN gene polymorphism is shown
in Table 21. No significant differences between the two patients groups were
observed. Allele 2 of the IL1RN polymorphism was found in 63/113 (.56) of
• . . 2
patients with mild disease compared with 35/77 (.46) with severe disease (x =1.94,
p=.163; OR 95%C.I. 0.37-1.18). Again no significant difference was observed
105
between patients with acute pancreatitis and healthy controls with respect to IL1RN
genotype.
Analysis of data derived from all individuals demonstrated a significant interaction
between ILip alleles and IL1RN alleles, such that carriers of IL1 p allele 2 had
reduced carriage of IL1RN allele 2. ILIRN allele 2 was found in 48/117 (.41) of
individuals carrying ILip allele 2 compared with 98/175 (.56) of individuals without
IL 1 p allele 2 (x2=6.29, p=.012). However, the carriage of the high secreting ILip
allele 2 along with non-carriage of the high secreting ILIRN allele 2 was not
associated with disease severity (x2=0.73, p=.392; OR 95%C.I. 0.67-2.72)
Finally there was no significant association between aetiological agent and cytokine
genotype for TNF-308 (x2=l-64, p= 950), TNFB (x2=2.50, p=.869), IL1B (x2=7.23,
p=.300) and ILIRN (x2=26.40, p=.192). Likewise there was no significant
association between the aetiological agent and the allele associated with high
secretion for TNF-308 (x2=l-02, p=.797), TNFB (xM.21, p=.750), IL1B (x2=3.94,
p=.267) and ILIRN (x2=0.98, p=.806).
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DiseaseTNF-308g notypeFB Severity1Homozygous/1eter1 2Homozygous2/21teroz
Milddisease Severediseas Acutepancreatitis Healthycontrols
71(.62) 51(.66) 122(.64) 65(.64)
40(.36) 20(.26) X2=5.32,p=.070 60(.32) 32(.31) x2=0.08,p=.964
2(.02) 6(.08) 8(.04) 5(.05)
16(.14) 9(.12) 25(.13) 16(.16)
48(.43) 41(.53) X-2.14,p=.344 89(.47) 47(.46) X2=0.36,p=.834
49(.43) 27(.35) 76(.40) 39(.38)
Table19:Frequencydistrib tioofthumournecrosisfact rg npolymorphisms. Frequencydistrib tioofthtumournecrosisfact rg np lym rphismi atientw ta upancr a itidhe lt yc tr l .Figur thenumberofindividualswithatgenotyp .Trelativfreq encytg normilds veredi sipar th ses.Comparison betweengroupsascarri do tus gthx2 t.
DiseaseILipgenotype Severity1Homozygous1/1etero 22
Milddisease70(.62) Severediseas48(.62) Acutepancreatitis118(.62) Healthycontrols57(.56)
38(.34)50 28(.37)101 X2=1.52,p=.468 66(.35)03 40(.39)55 X2=1.33,p=.514




Milddisease43(. 8)52466(.05)001(. 1)908(. )1(. 0) Severediseas38(.49)2735(.041. 1)(.009)(. 1.0 )( 0 X2=5.86,p=.556 Acutepancreatitis81(.42)7919(.051)(. 1608)2(..01)( 0 Healthycontrols50(.49)3333(. )00(. )1132(.01). 0( ) X2=7.72,p=.461 Table21:Frequ ncydistrib tionofthIL RNgenepolymorphism. Frequencydistrib tionofthIL1RNgenepolymorphismnatie tsw tacutep ncreatitisdal hycontrols.Figthmberf individualswiththatgenotype.Ther lativefreq ncyoftgenotyperm ldsev rd aspar ntheses.Compari onb w groupswascarriedo tusingthy2e t.
Cytokine Phenotype In Acute Pancreatitis
In non-stimulated whole-blood culture the production of TNFa and ILip was below
the lower limit of detection (Figure 13 and Figure 14). In contrast after 8 hours
incubation with 5pg/mL of LPS, TNFa secretion was significantly increased in both
patient groups (Wilcoxon signed rank p<.001). There was no significant difference
in TNFa secretion between patients with previously mild [4136pg/mL (IQR
2996-4593)] and severe disease [3319pg/mL (IQR 3319-4833), Mann-Whitney U
p=.932]. Similarly after 8 hours incubation there was a significant increase in ILip
secretion (Wilcoxon signed rank p<.001). Again the increase in ILip secretion was
similar between the two patient groups [mild 2612pg/mL (IQR 2223-4076) vs severe
2937pg/mL (IQR 1914-3400), Mann-Whitney U p=.604],
IL1RA secretion was significantly increased following LPS stimulation
[unstimulated 285pg/mL (IQR 285-295) vs stimulated 2473pg/mL (IQR 1676-3230),
Wilcoxon signed rank p<.001] (Figure 15). Although stimulated IL1RA secretion
was higher in patients with severe disease the increase was not significant [mild
1995pg/mL (IQR 1289-3154) vs severe 2630pg/mL (IQR 2217-3394),
Mann-Whitney U p=.057]. However, the ratio of IL1P to IL1RA secretion was
significantly different between the two groups (Figure 16). Patients with previous
mild acute pancreatitis had a higher ILipTLIRA ratio when compared to those with
previous severe disease [mild 1.28 (IQR 1.01-2.29) vs severe 0.95 (IQR 0.73-1.79),
Mann-Whitney U p=.016]. There was no correlation between ILip and IL1RA






















Figure 13: Plot of supernatant TNFa concentration in whole blood
culture following recovery from acute pancreatitis.
Paired samples were either unstimulated or stimulated with 5pg/mL
lipopolysaccharide. Each point represents a single individual.
In patients with previous mild (n=26) and severe (n=25) acute pancreatitis
there was a significant increase in TNFa secretion following stimulation (Mild
Wilcoxon signed rank p<.001, Severe Wilcoxon signed rank p<.001). There
was no significant difference in stimulated TNFa secretion in patients with


















Figure 14: Plot of supernatant ILip concentration in whole blood culture
following recovery from acute pancreatitis.
Paired samples were either unstimulated or stimulated with 5pg/mL
lipopolysaccharide. Each point represents a single individual.
In patients with previous mild (n=26) and severe (n=25) acute pancreatitis
there was a significant increase in ILip secretion following stimulation (Mild
Wilcoxon signed rank p<.001, Severe Wilcoxon signed rank p<.001). There
was no significant difference in stimulated ILip secretion in patients with mild






















Figure 15: Plot of supernatant IL1RA concentration in whole blood
culture following recovery from acute pancreatitis.
Paired samples were either unstimulated or stimulated with 5(ig/mL
lipopolysaccharide. Each point represents a single individual.
In patients with previous mild (n=26) and severe (n=25) acute pancreatitis
there was a significant increase in IL1RA secretion following stimulation
(Mild Wilcoxon signed rank p<.001, Severe Wilcoxon signed rank p<.001).
Although stimulated IL1RA production was higher in patients with previous




















Figure 16: Plot of supernatant IL1f3:IL1RA concentration ratio in whole
blood culture following stimulation with 5pg/mL lipopolysaccharide.
Patients with previous mild acute pancreatitis (n=26) had a higher
ILip:IL1RA ratio when compared to those with previous severe disease
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Figure 17: Bivariate plot of ILip and IL1RA supernatant concentration.
Bivariate plot of ILip and IL1RA production in whole blood cultures following
incubation with 5pg/mL LPS. Individual points represent those with previous
mild (©) or severe disease (o ). Solid line represents the regression slope
whilst dotted lines represent the 95% confidence intervals.
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Haematological Indices And Cytokine Secretion
The differential full blood counts for the two patient groups are shown in Table 22.
Comparison between the two patient groups revealed a significant difference in
monocyte count between patient groups [mild 0.195xl09/L (IQR 0.150-0.280) vs
severe 0.290xl09/L (IQR 0.210-0.333), Mann-Whitney U p=.030]. The normal
reference range for monocyte count is 0.2 to 0.8x109/L. There was no significant




Neutrophils (xl09/L) 4.25 (3.23-5.29) 3.87(3.12-5.47) Mann-Whitney U p=.699
Lymphocytes (xl09/L) 1.71 (1.49-2.47) 2.07 (1.73-2.20) Mann-Whitney U p=. 155
Monocytes (xl09/L) 0.20 (0.15-0.28) 0.29 (0.21-0.33) Mann-Whitney U p=.030
Eosinophils (xl09/L) 0.15 (0.11-0.24) 0.18(0.12-0.27) Mann-Whitney U p=.492
Basophils (xl09/L) 0.04 (0.03-0.07) 0.06 (0.04-0.08) Mann-Whitney U p=.318
Platelets (xl09/L) 246(219-262) 217(190-291) Mann-Whitney U p=.391
Haemoglobin (g/L) 137(124-148) 137 (130-146) Mann-Whitney U p=.706
Table 22: Differential full blood counts of patients participating in
cytokine phenotype studies.
Stated values are median (interquartile range).
In order to identify potential relationships between haematological indices and
cytokine concentrations in stimulated whole blood cultures, backward stepwise
regression models were created. Within a stepwise regression model stimulated
TNFa secretion was significantly associated with monocyte count
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(F=4.50, p=.037; intercept F=79.31), but not associated with neutrophils (F=.03),
lymphocytes (F=.36), eosinophils (F=.l 1), basophils (F=.02), platelets (F=.37) and
haemoglobin (F=1.58). Therefore to correct for any influence ofmonocyte count on
observed phenotype, corrected TNFa secretion was calculated. However, the
production of TNFa per monocyte was similar between the two groups [mild
18517ng/mL/1010monocytes/L (IQR 12226-29993) vs severe
12979ng/mL/1010monocytes/L (IQR 10479-20046), Mann-Whitney U p=.077].
In contrast, stimulated IL1[3 production did not correlate with any haematological
parameter [neutrophils F=.58, lymphocytes F=1.48, monocytes F=.08, eosinophils
F=.46, basophils F=.25, platelets F=.08 and haemoglobin F=.51: intercept F= 26.00
p=.229],
IL1RA secretion correlated significantly with neutrophil count (F=27.75, p<.001;
intercept F=4.36). ILIRA secretion did not correlate with any other parameter
(lymphocyte F-.36, monocytes F=.57, eosinophils F=.71, basophils F=2.78, platelets
F=.02 and haemoglobin F=.09). Therefore ILIRA concentrations were corrected for
neutrophil count. With this correction ILIRA secretion was significantly higher in
patients with previous severe disease when compared to those with previous mild
disease [mild 470pg/mL/10loneutrophils/L (IQR 352-652) vs severe
675pg/mL/10loneutrophils/L (IQR 498-812), Mann-Whitney U p=.007].
Association Between Cytokine Phenotype And Genotype
No significant correlation was observed between TNFa secretion and TNF-308
genotype (Kruskal-Wallis p=.611), the carriage of TNF-308 allele 2 (Mann-Whitney
U p=.784), TNFB genotype (Kruskal-Wallis p=.986) or the carriage of TNFB allele
2 (Mann-Whitney U p=.324).
Only two individuals were homozygous for allele 2 of the IL1 [3 polymorphism,
preventing analysis of the effect of IL113 genotype on ILip secretion, however
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carriage of allele 2 was not associated with increased secretion of ILip
(Mann-Whitney U p=.705).
Four IL1RN genotypes were observed, and no significant association between
genotype and IL1RA secretion was detected (Kruskal-Wallis p=.582). Further, there
was no association between the carriage of IL1RA allele 2 and IL1RA secretion
(Mann-Whitney U p=.924).
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Enteral Nutrition In Prognostically Severe Acute Pancreatitis
Delivery Of Enteral Nutrition
Of fourteen patients randomised to receive enteral nutrition, nasojejunal tube
placement was successful in 12 (86%). One patient randomised to receive enteral
nutrition refused tube placement but was willing to participate in the study and
therefore his results are included in the conventional therapy group. In the other
patient the nasojejunal tube could not initially be passed through the pylorus but later
passed spontaneously into the duodenum allowing enteral feeding. The duration of
radiological screening was a median of 3.0 minutes (range 0.9-11.9). The median
number of tube dislodgements was 1 (range 0-3) per person. Tubes remained in
place for a median of 2 (range 1 -7) days. The median number of tube placements
was 1 (range 1-3) per person. The percentage of nutritional requirements delivered
through enteral nutrition is shown in Figure 18. The delivery of enteral nutrition in
the cohort remained relatively constant averaging a median 21% (range 0-100%) of
predicted daily calorific requirement over the first 5 days. Over the first 5 days a
median of 1.8 (range 0-7.3) megajoules/day was delivered. After this period the
majority returned to normal diet. Patients unable to establish normal diet at this stage
were also less able to tolerate enteral nutrition because of established ileus and this is
reflected in the decrease in the percentage of calorific requirement delivered enterally
after day 5. By day 10 no patient in this study was receiving artificial enteral
nutrition. In 3 patients the volume of feed was limited by ileus. Three patients in
this study received parenteral nutrition within the study period. Parenteral nutrition
was commenced on day 4 in one patient in the enteral nutrition group because of
profound ileus and high nasogastric aspirates (calorific requirements delivered by the
parenteral route are excluded in this patient). Two patients in the conventional group
commenced parenteral nutrition on days 2 and 7 respectively at the discretion of the
treating physician.
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For each patient group the volume of intravenous fluid therapy, oral fluid intake and
urine output over the first four days of the study period is shown in Figure 19. There
were no significant differences in intravenous fluid therapy (ANOVA p=.338), oral
fluid intake (ANOVA p=.548) or urine volume (ANOVA p=.520) between the two
patient groups. Further, as shown in Figure 20, urinary nitrogen excretion was
similar between the two patient groups (ANOVA p=.497).
Normal diet was re-introduced at a median of 5 (range 4-9) days in patients receiving
enteral nutrition compared with 6 days (range 4-10) for the conventional group
(Mann-Whitney U p=.664). Two patients in the enteral group did not start normal
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Change In Markers Of The Inflammatory Response
As the median delay to introduction of normal diet was 5 days and the aim of the
study was to examine the effect of enteral nutrition on the systemic inflammatory
response, statistical analysis was carried out on results obtained from the time of
admission until day 4. Change in serum markers of the inflammatory response is
seen in Figure 21. Serum IL6 levels fell significantly (ANOVA p=.009) during the
study period in patients receiving enteral nutrition and in those receiving
conventional treatment. Serum sTNFR-I remained relatively constant (ANOVA
p=.952). Serum CRP concentrations increased from admission to day 2 and then fell
(ANOVA p=.006). The introduction of enteral nutrition did not affect the
concentrations of serum IL6 (ANOVA p=.281), serum sTNFR-I (ANOVA p=.531)
or serum CRP (ANOVA p=.624) over the first 4 days of the study period.
Change in IgG anti-endotoxin core antibody antibody concentrations is shown in
Table 23. The introduction of enteral nutrition did not significantly affect























Table23:Concentrationfanti-endocabIgGa tibodydur ngthfirst4ysfadmiss o . Statedvaluesrmedian(rang ).
Safety And Tolerance Of Early Enteral Nutrition
The results of nausea scores are shown in Figure 22. Although patients allocated to
the enteral nutrition arm had higher nausea scores than patients in the conventional
group (ANOVA p=.032), enteral nutrition did not significantly affect nausea
(ANOVA p=.228).
One patient had probable feed-induced diarrhoea. There were no major
complications that were directly attributable to enteral nutrition.
Gut Permeability To Non-Metabolised Sugars
The effect of enteral nutrition on gut permeability to non-absorbable sugars is shown
in Table 24. In the group receiving enteral nutrition 4 patients had normal intestinal
permeability at admission, however by the fourth study day 3 of these individuals
had developed abnormal results (in the remaining individual sugar permeability
studies were not possible). In contrast, 5 patients in the conventional group had
abnormal results on admission and normal results on day 4.
Organ Dysfunction Scores
The Marshall organ dysfunction scores over the first four days of admission are
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Discussion
Kinetics Of Serum Soluble E-Selectin And P-Selectin In Acute
Pancreatitis
The present study demonstrates that during the first 3 days of admission,
concentrations of serum soluble E-selectin increase in patients with severe acute
pancreatitis, whilst remaining relatively constant in patients with mild disease. In
contrast concentrations of serum soluble P-selectin fall significantly over the first
three days, with no significant difference between patients with mild or severe acute
pancreatitis, although levels were always higher in those with severe disease.
However, serum P-selectin concentrations were significantly higher in non-survivors
than survivors.
Although modern classification systems divide disease severity into mild or severe
depending on a number of clinical criteria ', in practice there is a continuum of
disease severity. In order to observe the role of endothelial-derived selectins in acute
pancreatitis the study sample consisted of patients at the extreme ends of the
spectrum thereby minimising the sample size that would be required to detect any
differences in serum soluble E-selectin and P-selectin concentrations. Although the
degree of organ dysfunction has not been quantified, it is clear from the outcome of
patients with severe acute pancreatitis that this patient group had profound organ
dysfunction. Finally, by excluding patients with other active disease processes, it is
likely that any differences observed between the two patient groups were due solely
to the acute pancreatitis.
Because E-selectin is shed from endothelial cells following activation, soluble
E-selectin has been used as a marker of endothelial cell 209. Intravenous
administration of tumour necrosis factor a 340 or lipopolysaccharide 34', both of
which are implicated in the pathogenesis of severe acute pancreatitis 92>96>317-319,342^
cause dose-related increases in the levels of serum soluble E-selectin. Further, in
critically ill patients with organ dysfunction arising from a systemic inflammatory
response, levels of serum soluble E-selectin correlate with the degree of
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haemodynamic compromise 343 and organ dysfunction 343"345. Soluble E-selectin
would therefore appear to be a reliable marker of endothelial cell activation in
conditions such as acute pancreatitis in which organ dysfunction is a consequence of
the systemic inflammatory response.
Previous reports regarding serum soluble E-selectin in acute pancreatitis have been
incomplete. In a randomised placebo controlled trial of lexipafant , a platelet
activating factor (PAF) antagonist, initial concentrations of serum soluble E-selectin
were similar in patients with mild or severe disease; in keeping with the present
observations. However, although levels of serum soluble E-selectin decreased over
the following 2 days in patients receiving lexipafant or placebo, no comparison
between patients with mild or severe disease was reported. In a similar fashion,
Inagaki and colleagues 346 have reported that serum soluble E-selectin is increased 72
hours after pain onset, returning to normal at 168 hours. However, no comparison to
patients with mild disease was made. In contrast to the previous two studies, in the
present study significant differences between levels of serum soluble E-selectin
between mild and severe acute pancreatitis were observed. These observations are in
concordance with those ofHynninen and colleagues 347 who observed levels of
serum soluble E-selectin in 9 patients with prognostically severe acute pancreatitis as
defined by either an APACHE II score of 9 or more, or a Balthazar grade of D
or E. Although mean levels of serum soluble E-selectin remained relatively constant
over the first few days for the complete cohort, when analysed with reference to
organ dysfunction severity scoring, patients with marked organ dysfunction
developed significantly higher levels of serum soluble E-selectin on days 2 and 3, a
pattern similar to that observed in the present study. Moreover the present
observation that increased endothelial cell activation occurs in patients with severe
acute pancreatitis when compared to those with mild disease is further corroborated
by Chaloner and colleagues who reported that levels of von Willebrand factor,
another putative marker of endothelial cell activation, were higher in patients with
severe acute pancreatitis when compared to patients with mild disease.
132
In contrast to the consensus belief that E-selectin is a specific marker of endothelial
cell activation, the significance of serum soluble P-selectin levels is still
controversial. Although P-selectin is found in the membrane of endothelial cell
Weible-Palade bodies, it is also a constituent of the platelet a-granule membrane,
demonstrating surface expression following platelet activation 349' 35°. Although
soluble forms of P-selectin may arise either through proteolytic cleavage of cell
surface P-selectin or through the production of alternatively spliced isoforms missing
the transmembrane region 35', neither form appears to be exclusively produced by
one cell type. Attempts at correlating levels of serum soluble P-selectin with other
markers of either endothelial cell or platelet activation have also proved unhelpful in
908 ^S9
determining the source of serum soluble P-selectin in vivo ' , possibly because
P-selectin is a membrane constituent whilst the other markers measured are soluble
components of secretory granules. Furthermore, in patients with the systemic
inflammatory response syndrome it is likely that endothelial and platelet activation
co-exist, therefore serum soluble P-selectin may be derived from either cellular
source. The previously reported observations that signs of activation of the
coagulation system, including reductions in platelet counts, are common in patients
with acute pancreatitis suggests that concomitant endothelial cell and platelet
activation occurs in acute pancreatitis 353"355.
Although it is not possible to confirm the exact source of serum soluble P-selectin in
patients with acute pancreatitis, the observation that serum soluble P-selectin
concentrations do not correlate with the platelet count suggest that it is derived
mainly from endothelial cells. If the measured serum soluble P-selectin was derived
from platelets it may be expected that P-selectin levels would be highest in the
patients with the greatest levels of platelet activation. In the present patient
population, those with the highest level of platelet activation would be those who
paradoxically had the lowest platelet count as a result ofwidespread activation of the
coagulation system 3~6. In keeping with this supposition, platelet count demonstrated
a significant negative correlation with concentrations of serum soluble E-selectin,
suggesting platelet activation and consumption alongside endothelial activation. In
contrast P-selectin concentration did not correlate with platelet count.
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Although no significant difference in P-selectin levels was observed between patients
with mild or severe disease, the observation that levels were significantly higher in
non-survivors and that serum concentrations fell over the first three days suggest that
P-selectin has a role in the pathogenesis of acute pancreatitis. Further supporting the
role of P-selectin in the pathogenesis of severe acute pancreatitis is the observation
that in an experimental model of acute pancreatitis up-regulation of P-selectin
expression occurs in the lungs and that immunoneutralisation of P-selectin
ameliorates pulmonary neutrophil infiltration 190.
Within the present study there appeared to be differential expression of
endothelial-derived selectins. P-selectin expression occurred early in all patients
with acute pancreatitis, with increased E-selectin expression occurring later and
confined to those with severe disease. It is not clear what mechanisms are
responsible for generalised expression of P-selectin but selective expression of
E-selectin. However, the observed temporal patterns of serum soluble selectins
would be in keeping with the previously observed early expression of pre-formed
and stored P-selectin and the late expression of E-selectin following de-novo
synthesis. Moreover the present observations of differential selectin expression are
in keeping with those derived from an experimental model. Using a dual
radio-labelled monoclonal antibody technique, Lundberg and colleagues 210
demonstrated early expression of P-selectin in all major organs bar the kidney, whilst
expression of E-selectin occurred later and was confined to the lungs. Interestingly
the expression of P-selectin appeared to be biphasic with a further late peak
coinciding with the peak of E-selectin and presumed to be due to late de-novo
synthesis of P-selectin. The failure to observe such a biphasic pattern of serum
soluble P-selectin concentrations within the present study may be due to the
relatively short duration of sampling.
In conclusion, the present study provides evidence of a strong association between
endothelial-derived selectins and the development of organ dysfunction in acute
pancreatitis. In addition the results confirm the importance of endothelial cell
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activation as part of the systemic inflammatory response in patients with acute
pancreatitis.
Cytokine Genotype And Phenotype In Acute Pancreatitis
Although environmental factors trigger cytokine secretion, genetic factors may be
important in determining levels of secretion 225. In vitro studies have identified that
individuals may demonstrate consistent differences in leukocyte cytokine secretion
and that these differences are probably genetically pre-determined
Genetically-determined differences in levels of cytokine secretion following a
stimulus may explain individual differences in disease severity in inflammatory
disorders such as acute pancreatitis.
The present observational study tests the hypothesis that patients with severe acute
pancreatitis have higher levels of pre-determined pro-inflammatory cytokine
secretion than patients with mild disease by examining the distribution of cytokine
gene polymorphisms associated with variation in TNFa, IL1P and IL1RA secretion.
The results show no correlation between the gene polymorphisms studied and disease
severity. Further, comparison of genotype frequencies in patients with acute
pancreatitis and in healthy individuals suggests that these polymorphisms do not
influence disease susceptibility. Finally, within the present study there was no
correlation between the cytokine gene polymorphisms studied and levels of in vitro
cytokine production.
Within the limits of current evidence it is not possible to state with certainty whether
the polymorphisms studied are the most important markers of genetically determined
cytokine secretion. Therefore in order to ascertain whether patients with severe acute
pancreatitis are indeed "high secretors" of cytokines, phenotype studies were
undertaken. These studies were carried out following recovery from an episode of
acute pancreatitis thereby minimising the influence of environmental factors and
leukocyte down-regulation during the acute illness ' . Clearly, non-survivors
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were not included in this group and it is not possible to exclude different patterns of
responsiveness in patients dying of acute pancreatitis. However, within these
limitations the present results demonstrate that levels of leukocyte TNFa secretion
are similar in patients with previously mild or severe acute pancreatitis. However,
although ILip and IL1RA secretion was similar in the two patient groups, a
significant difference in the IL1 (TIL1RA ratio was observed such that patients with
previously mild disease had an increased ratio. This difference may be the result of
increased secretion of IL1RA in patients with severe acute pancreatitis.
Monocyte secretion ofTNFa is increased in patients with severe acute pancreatitis.
McKay and colleagues 99 have demonstrated increased monocyte secretion of TNFa
in patients with severe acute pancreatitis. The observation that following recovery
leukocyte secretion ofTNFa is similar in all patients suggests that environmental
factors are the principal modulators of leukocyte TNFa secretory responses.
There are several potential reasons for failing to observe any association between
cytokine gene polymorphisms and levels of cytokine secretion. Although
polymorphisms may only be markers of other functionally significant gene
polymorphisms at least one of the polymorphisms examined in this study is known to
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have functional significance " ' . The TNF-308 gene polymorphism would
appear to occur at a transcription factor binding site in the TNFa promoter213>214 and
therefore affects protein binding thereby altering transcriptional activity 214.
However, other data including the present study have cast doubt upon the functional
significance of the TNF-308 polymorphism 216>224>2255 although differential TNFa
secretion may be cell and stimulus specific 2I7. Although the failure of the present
study to observe differential TNFa secretion associated with the TNF-308
polymorphism may be due to an inappropriate stimulus other possibilities exist. In
complex biological systems the effect of a single gene polymorphism in determining
cytokine secretion may be minimised through the interaction of other factors. The
increased potential for interacting systems in whole blood culture may explain the
failure of the present study and others research groups to demonstrate an association
between TNF gene polymorphisms and increased secretion of TNFa in whole blood
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culture 224'225. it is perhaps, therefore, not surprising that single gene polymorphisms
do not correlate with outcome in patients with severe acute pancreatitis.
One other study has investigated interleukin 1 gene polymorphisms in patients with
acute pancreatitis 252. As in the present study, no association was found between the
ILip Taql polymorphism and disease susceptibility and severity. However, in
contrast to the present study, Smithies observed an increased rate of carriage of
IL1RN allele 1 in patients with acute pancreatitis when compared to healthy
individuals, and an increased rate of carriage of IL1RN allele 1 in patients with
• • ... 252
severe acute pancreatitis when compared to those with mild disease . These
observations led to the suggestion that the IL1RN gene polymorphism has a role in
determining both disease susceptibility and severity. However, if the present
observations are combined with the results published by Smithies and colleagues,
... 2IL1RN genotype has no association with disease susceptibility (x =9.44, p=.223) or
# 2
severity (x =7.14, p=.414), nor does the carriage of IL1RN allele 1 have an
association with disease susceptibility (x2=3.67, p=.055) or severity (x2=0.31,
p=.580). It would therefore appear that the IL1RN VNTR polymorphism does not
play a major role in the pathogenic mechanisms of acute pancreatitis.
Although the observation of an increased ratio of IL1P to IL1RA in patients with
mild acute pancreatitis would appear to be paradoxical, it may be a real and
• • • TSR
important biological observation. Heresbach and colleagues have recently
reported that during an episode of severe acute pancreatitis patients have a reduced
serum ILip.'ILlRA ratio. This alteration in the ILipdLIRA ratio in patients was
due mainly to an increase in secretion of IL1RA rather than a reduction in ILip
secretion. These observations are in keeping with the present results in which there
was no difference in ILip secretion between the two groups but a trend towards
increased secretion of IL1RA in patients with previous severe disease leading to a
significantly lower IL1 P:IL1RA ratio. Further, when corrected for differences in
differential blood counts, patients with previous severe disease had significantly
greater secretion of IL1RA than those with mild disease. It would appear logical that
a lower IL1 P:IL1RA ratio would be associated with a lesser inflammatory response
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than higher ratios and therefore the present observation and that of Heresbach would
appear to be paradoxical given that organ dysfunction in acute pancreatitis is
believed to be due to a systemic inflammatory response. However, the relationships
between ILlp, IL1RA and both membrane associated and soluble interleukin 1
receptors in determining a biological response is as yet unclear. For example,
although IL1RA is a pure antagonist on membrane associated interleukin 1 receptors,
it can bind to soluble interleukin 1 receptors, displacing bound bioactive IL1P
Further, the importance of anti-inflammatory mechanisms in determining outcome in
inflammatory conditions may be underestimated and poorly understood. Evidence
exists suggesting that an excessive anti-inflammatory response in septic patients is
ftQ 1ft TTC
detrimental to outcome ' ' and may be the result of innate differences
Taken together with the findings ofHeresbach 35 , the present observations suggest
that pre-determined individual differences in the interleukin 1 system may be
involved in mediating disease severity in acute pancreatitis. However, because
cytokine phenotype was not determined during the in-hospital stay, no association
between cytokine phenotype during and after and episode of acute pancreatitis can be
conclusively assumed to exist, and therefore further studies are required to confirm
the significance of the present observations before a pre-determined association is
definitively established.
Finally, this study has only examined the genotype and phenotype of TNFa, IL1 p
and IL1RA and it is likely that further functional gene polymorphisms will be
described which may have a role in determining disease severity in acute
pancreatitis.
In conclusion the present study demonstrates that polymorphisms at the TNF and
IL1 gene loci do not have a principal role in the regulation of disease severity in
acute pancreatitis. In complex biological disease processes such as acute
pancreatitis it is unlikely that single gene polymorphisms will regulate disease
outcome. Further, as the present study of leukocyte TNFa and ILip secretory
phenotype in patients following an episode of acute pancreatitis shows no difference
in leukocyte responsiveness between patients with mild and severe disease, it is
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unlikely that any future identification of functional polymorphisms at these gene loci
will alter the role of single gene polymorphisms in regulating outcome in this
disease. In contrast, the present findings of a reduced IL1 P:IL1RA ratio in patients
with severe disease suggests that future studies should focus on the complex
interaction between pro-inflammatory and anti-inflammatory mechanisms regulating
the inflammatory process in acute pancreatitis.
Enteral Nutrition In Prognostically Severe Acute Pancreatitis
A principal focus of current research interest in severe acute pancreatitis is the
development of effective therapies based on an improved understanding of the
pathogenic mechanisms of this disease. In view of experimental and clinical
evidence suggesting that gut dysfunction may contribute to the systemic
inflammatory response seen in patients with acute pancreatitis a rational approach is
the development of therapies limiting the effects of fasting and critical illness on the
intestinal tract. Because studies in other critical illness states have demonstrated a
reduction in infective complications in patients receiving enteral nutrition it is
rational to hypothesise that similar benefits may be obtained in patients with acute
pancreatitis. However, valid concerns exist regarding the potential for adverse
stimulation of the inflamed pancreas by the presence of nutrition in the upper
gastrointestinal tract. Moreover the feasibility of enteral feeding in patients with
severe acute pancreatitis, in whom intestinal ileus may be a significant problem, has
not been fully determined. Therefore the present study has focused on the
practicalities of instituting early enteral nutrition in patients with prognostically
severe acute pancreatitis as well as the effects of enteral nutrition on surrogate
markers of the inflammatory response.
In order to minimise any potential pancreatic stimulation feed was delivered via
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nasojejunal tubes positioned radiologically beyond the ligament of Treitz . Initial
tube placement was successful in 86% of patients comparing favourably with a large
series of fluoroscopically-placed tubes reported by Gutierrez 362. However, although
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successful tube placement can be readily achieved the present data suggest that tube
dislodgement is common, reducing tube lifespan. Indeed in the present study the
median tube lifespan was considerably shorter than may be expected from other
"lf/i
published data . However, despite difficulties in maintaining tube position, no
significant complications occurred that could be directly attributable to enteral
feeding, suggesting that nutritional support using the enteral route is safe. One
practical solution to the problem of naso-enteric tube dislodgement may be the use of
endoscopically placed clips securing the feeding tube to the bowel wall (CW Imrie -
personal communication). A further solution to the problem of nasojejunal feeding is
the use of nasogastric feeding tubes, which although remain prone to dislodgement
are simpler to site. A recent observational study has suggested that nasogastric
feeding is feasible, with acceptable rates of failure due to gastric stasis 364.
In the present study no effect of early enteral nutrition on markers of the
inflammatory response or on organ dysfunction in patients with predicted severe
acute pancreatitis was observed. This suggests that enteral nutrition at the level
provided in this study does not ameliorate, and probably more importantly does not
exacerbate, the inflammatory response in acute pancreatitis. The present
observations are however different from previously reported studies. Windsor and
^9 ft
colleagues have reported a reduction in the systemic inflammatory response and
in surrogate markers of bacterial translocation in 34 patients with acute pancreatitis
receiving enteral nutrition when compared to those receiving parenteral nutrition.
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Similarly McClave has reported a more rapid normalisation of the physiological
disturbance in 30 patients receiving enteral nutrition when compared to those
receiving parenteral nutrition. The differences between the present study and the
other two may arise for several reasons.
Firstly and perhaps most importantly a median of 1.8 megajoules/day was delivered
which constituted a median of 21% of daily calorific requirement. Although, the
original intention was to provide as close to complete calorific requirements as
possible, a cautious step-up protocol was selected to avoid feed-induced nausea,
vomiting and the risk of feed aspiration. As reflected by the lack of difference in
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nausea scores between the two patient groups and the absence ofmajor feed-induced
complications this strategy appears to have been successful. However, Windsor
T9 f\
delivered approximately 65% of non-protein calories over the study period , whilst
McClave provided 71% of caloric requirements 325. Although the high rate of tube
dislodgement may account for some of the discrepancy between ourselves and the
other two studies, the difference in disease severity of patients in the two studies
when compared to the present patient population may also be a factor. The patient
population in the studies reported by Windsor and McClave had lower serum
C-reactive protein concentrations and multiple factor prognostic scores than patients
included in the present study indicating that the present study consisted of a patient
population with greater disease severity. The preponderance of patients with mild
acute pancreatitis in the studies of Windsor and McClave suggest that the majority of
patients had minimal intestinal ileus and therefore maximal rates of feeding could be
achieved without difficulty. In the present population of patients with more severe
disease intestinal ileus is a significant problem, indeed in almost 25% of patients feed
volumes had to be limited because of intestinal ileus. Although Kalferentzos and
colleagues have demonstrated that 74% of calorific requirements could be supplied
through enteral nutrition in severe acute pancreatitis this value was the mean value
over a period of 35 days 327. No value for the initial days following admission is
provided by Kalferentzos, and it is likely that intestinal ileus is maximal just after
admission to hospital. Indeed with respect to early intestinal ileus it is interesting to
note that although McClave provided 71% of nutritional requirements during the
total study period only 30% could be provided during the first 4 study days.
However, it is not clear whether delivery of full caloric requirements by enteral
nutrition is required to obtain benefit. It has been postulated that so-called minimal
enteral nutrition is able to provide enough luminal nutrition to maintain intestinal
function thereby limiting the effects mediated by the intestinal tract in the systemic
inflammatory response syndrome. Experimental studies have demonstrated that
minimal enteral nutrition maintains intestinal mass but does not necessarily affect
intestinal tract immune function 365,366. However, the addition ofminimal enteral
nutrition to parenteral nutrition in neonates requiring surgery is associated with an
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improvement in systemic immune function . The present results however suggest
that minimal enteral nutrition does not modify the inflammatory response. More
interestingly the present study observed an alteration in intestinal function as
measured by intestinal permeability in patients receiving enteral nutrition. This
observation is in contrast to evidence suggesting that enteral nutrition improves
intestinal permeability in critical illness states 27\ The mechanisms responsible for
this apparent deterioration of intestinal permeability are not clear. Although
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hypertonic solutions can cause an increase in intestinal permeability ' , Jevity is
an isotonic solution. Bacterial colonisation secondary to the enteral feeding tubes is
another possible explanation but the apparent increase in abnormal intestinal
permeability in patients receiving early enteral nutrition was not paralleled by altered
IgG endotoxin antibody levels suggesting that there was no concomitant increase in
bacterial translocation.
Another major difference between the present study and those of Windsor and
McClave is the use of parenteral nutrition 325'326. In line with published guidelines,
patients in the present study did not receive parenteral nutrition from admission. In
contrast, in both of the other studies patients in the parenteral nutrition group
received nutritional support from admission. Parenteral nutrition was therefore given
to patients with mild disease, a group of patients that do not require routine artificial
nutritional supplementation. More significantly however, Windsor and colleagues
maintained a nil-by-mouth regime in the group receiving parenteral nutrition until the
seventh study day irrespective of the clinical condition, therefore a group of patients
remained fasted despite clinical resolution of the disease. The delivery of parenteral
nutrition to patients with mild disease and the abstinence until the seventh day may
account for the observed differences. Fong and colleagues 370 have demonstrated
that bowel rest and the institution of parenteral nutrition in normal volunteers is
associated with an increased inflammatory response following a stimulus, whilst
Welsh and colleagues 371 have reported that malnourished patients have an
impairment of intestinal function and increased markers of the acute phase response.
Therefore observed differences between patients receiving parenteral or enteral
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nutrition may not arise from a modulation of the disease process but may in fact be a
direct consequence of the treatment modality.
Another reason for the failure to observe any effect on the inflammatory response
may be a result of the earlier sampling on day 4 in the present study in comparison to
day 7 as in the trial reported by Windsor. Measurement of the inflammatory
response at day 4 may reflect the level of pancreatic inflammation and may be
marginally be influenced by the effects of bacterial translocation. Therefore by day 4
the effects of enteral nutrition may not yet be apparent.
Although McClave 325 reported an improvement in the physiological disturbance as
T79
manifested by normalisation of Ranson's criteria no effect of enteral nutrition on
organ dysfunction as measured by the Marshall score was observed in the present
study. However, the median organ dysfunction score was 1 out of a possible 24
points indicating that in a mixed population of intensive care and high dependency
unit patients the Marshall organ dysfunction score does not have sufficient
sensitivity. Although serial Ranson's 372, Glasgow 321 and APACHE II 329 scores
have been used to monitor physiological disturbance in acute pancreatitis none of
these systems was developed or validated for this purpose. An accurate
physiological scoring system for this population of patients is therefore required.
Although surrogate markers such as C-reactive protein and organ dysfunction scores
are frequently used, benefits in these measure are not necessarily sufficient to
mandate a change in management. Ofmore importance are outcome measures such
as mortality and major complications. Therefore the results from Kalferentzos'
group demonstrating a reduction in total and septic complications from the use of
enteral nutrition in patients with severe acute pancreatitis are exciting 327. However,
the ascribed benefits need to be confirmed in a larger study.
In summary, the present study demonstrates that although enteral nutrition is
feasible in patients with prognostically severe acute pancreatitis, early enteral
nutrition does not ameliorate or exacerbate the inflammatory response. With a
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growing body of experience attesting to the clinical safety of this technique, and
other small trials suggesting clinical benefit, a large multicentre trial is required to




The present studies have provided further insight into the pathogenic mechanisms in
acute pancreatitis and have evaluated a novel therapeutic intervention.
Through the determination of the kinetics of serum soluble E and P-selectin,
evidence has been provided confirming the role of the endothelium in the mediation
of severe acute pancreatitis. Moreover a differential pattern of serum soluble
endothelial-derived selectins has been observed which is in keeping with the known
biology of endothelial-derived selectins.
Further, the basis for the differential pattern of cytokine secretion observed in
patients with mild and severe acute pancreatitis has been examined. To this end the
frequency of polymorphisms which are associated with levels of cytokine secretion
have been determined. No association was observed between tumour necrosis factor
and interleukin 1 gene polymorphisms and disease severity within the present study
population. However, cytokine secretory phenotype studies performed following an
episode of acute pancreatitis phenotype studies have suggested that a pre-determined
difference exists in the interaction of the pro-inflammatory and anti-inflammatory
systems in patients with mild or severe acute pancreatitis. Future research should be
directed at understanding the importance of anti-inflammatory mechanisms and their
interaction with systemic pro-inflammatory mechanisms in determining the outcome
of critical illness states.
Finally, the results of a phase II/III randomised trial suggest that early enteral
nutrition is feasible in prognostically severe acute pancreatitis. However, no
significant outcome benefits were observed following the introduction of enteral
nutrition, although the small numbers included in the study preclude any definitive
conclusions. A large multicentre randomised trial is required before this therapeutic




Throughout this thesis the terminology used is concordant with the definitions
agreed at the International Symposium on Acute Pancreatitis held in Atlanta, USA in
September 1992 (Atlanta Consensus Conference) 1. This conference aimed to
standardise the terminology used in acute pancreatitis thereby providing a
framework upon which future research could be carried out.
Acute Pancreatitis
Acute pancreatitis is an acute inflammatory process of the pancreas, with variable
involvement of other regional tissues or remote organ systems.
Mild acute pancreatitis
Mild acute pancreatitis is associated with minimal organ dysfunction and an
uneventful recovery, and it lacks the described features of severe acute pancreatitis.
Severe Acute Pancreatitis
Severe acute pancreatitis is associated with organ failure and/or local complications
such as necrosis, abscess or pseudocyst. Organ failure is defined as shock (systolic
blood pressure less than 90mmHg), pulmonary insufficiency (Pa02 8kPa or less),
renal failure (creatinine level greater than 177pmol/L after rehydration) or
gastrointestinal bleeding (more than 500mL/24 hours). Systemic complications such
as disseminated intravascular coagulation (platelets 100xl0"3/mL and/or fibrinogen
less than l.Og/L and fibrin split products more than 80pg/mL) or severe metabolic
disturbance (serum calcium 1.87mmol/L or less).
Acute Fluid Collections
Acute fluid collections occur early in the course of acute pancreatitis, are located in
or near the pancreas and always lack a wall of granulation or fibrous tissue.
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Pancreatic Necrosis
Pancreatic necrosis is a diffuse or focal area(s) of nonviable pancreatic parenchyma
which is typically associated with peri-pancreatic fat necrosis. Contrast-enhanced
computed tomography is the current gold standard for the clinical diagnosis of
pancreatic necrosis.
Acute Pseudocyst
A pseudocyst is a collection of pancreatic juice enclosed by a wall of fibrous or
granulation tissue which arises as a consequence of acute pancreatitis, pancreatic
trauma or chronic pancreatitis.
Pancreatic Abscess
A pancreatic abscess is a circumscribed intra-abdominal collection of pus usually in
proximity to the pancreas containing little or no pancreatic necrosis which arises as a
consequence of acute pancreatitis or pancreatic trauma.
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Abbreviations
95%CI 95% confidence interval
APACHE II Acute physiology and chronic health evaluation II
CARS Compensatory anti-inflammatory response syndrome
CRP C-reactive protein
CT Computed tomography
DIC Disseminated intravascular coagulation
DNA Deoxyribonucleic acid
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-linked immunoabsorbant assay
ERCP Endoscopic retrograde cholangio-pancreatography
HLA-DR Human leukocyte antigen class DR





IL1B Interleukin 1P polymorphism in exon 5
IL1RA Interleukin 1 receptor antagonist
IL1R-I Interleukin 1 receptor type 1
IL1R-II Interleukin 1 receptor type 2




ISD Information and Statistics Division
L/R ratio Lactulose/rhamnose ratio
LPS Lipopolysaccharide
MAP kinase Mitogen-activated protein kinase
MODS Multiple organ dysfunction syndrome
mRNA Messenger ribonucleic acid
NFkB Nuclear factor kB
NSAIDs Non-steroidal anti-inflammatory drugs
OR Odds ratio
PAF Platelet activating factor
PCR Polymerase chain reaction
PEG Polyethylene glycol
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RFLP Restriction fragment length polymorphism
RPMI Roswell Park Memorial Institute
SEM Standard error of the mean
SIRS Systemic inflammatory response syndrome
SMR Scottish Morbidity Record
sTNFR-I Soluble tumour necrosis factor receptor type 1
sTNFR-II Soluble tumour necrosis factor receptor type 2
TNF Tumour necrosis factor
TNFa Tumour necrosis factora
TNFp Tumour necrosis factorp
TNF-308 Tumour necrosis factor a polymorphism at position -308
TNFB Tumour necrosis factor P polymorphism in intron 1
UK United Kingdom
USA United States of America
VNTR Variable number tandem repeat
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Anti-endotoxin core antibody ELISA
Cell culture plates
Corsafe® nasojejunal feeding tube
















Intestinal permeability sugar probes
Jevity® enteral nutrition





Polaroid Polapan 665 and 667 film
Polyacrylamide gel
Polymerase chain reaction reagents
Puregene® DNA isolation kit
Roswell Park Memorial Institute medium 1640
Serum CRP fluorometric immunoassay
Soluble E-selectin ELISA
Soluble P-selectin ELISA
Coaset Endocab Chromogenix, Molndal
Sweden
Corning Costar, High Wycombe UK









Sysmey NE8000, Toa Medical Electronics,
Japan
Hybaid, Teddington, UK
Sigma-Genosys Ltd, Cambridge UK
R&D Systems Europe, Abingdon, UK
Sigma-Genosys Ltd, Cambridge UK
R&D Systems Europe, Abingdon, UK
Oswell DNA Service, Southampton UK
CLB, Amsterdam Holland





FMC Bioproducts, Rockland, Maine, USA
Roche Diagnostics, Lewes UK
Edinburgh Camera, Edinburgh UK
Biorad, Hemel Hempstead, UK
Promega, Southampton UK
Gentra systems, North Carolina, USA
Life Technologies, Paisley, UK
Abbott, Berkshire UK
R&D Systems, Abingdon UK
R&D Systems, Abingdon UK
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